100 Cardiology VIVA Essentials: MASTER LIST

100 Cardiology VIVA Essentials: MASTER LIST

I. HEART FAILURE & HEMODYNAMICS (20 QUESTIONS)

II. VALVULAR HEART DISEASE (20 QUESTIONS)

III. CORONARY ARTERY DISEASE & ACUTE MI (20 QUESTIONS)

IV. ARRHYTHMIAS & ELECTROPHYSIOLOGY (20 QUESTIONS)

V. SYSTEMIC & CONGENITAL HEART DISEASE (20 QUESTIONS)

I. HEART FAILURE & HEMODYNAMICS (20 QUESTIONS)

1. Explain the Frank-Starling Law in the context of LV failure.

Response Template: Physiological Principle: The force of ventricular contraction is proportional to the initial resting length of the myocardial fibers (preload). Pathophysiology in HF: The Frank-Starling curve flattens and shifts downward. An increase in preload (LVEDP) no longer generates a proportional increase in stroke volume; instead, it causes pulmonary congestion. Guideline Application: Diuretics and venodilators (Nitrates) reduce preload, moving the patient leftward on the flattened curve, relieving congestion without significantly dropping cardiac output.
Cross-Examination (5 Q&A):

Q: What determines the "optimal" sarcomere length? A: Approximately 2.2 micrometers, maximizing actin-myosin cross-bridge overlap.
Q: How do inotropes affect the curve? A: They shift the curve upward and to the left (increased contractility independent of preload).
Q: Why does the curve flatten in HFrEF? A: Depleted ATP, down-regulation of beta-receptors, and intrinsic contractile dysfunction.
Q: What is the clinical correlate of crossing the "knee" of the curve? A: Acute pulmonary edema.
Q: How does afterload reduction help? A: It unloads the ventricle, shifting the curve upwards, allowing better stroke volume for the same preload.

2. How does the "Venturi effect" worsen obstruction in HCM?

Response Template: Physiological Principle: According to Bernoulli's principle, as blood velocity increases through a narrowed orifice (the LVOT), local pressure drops. Pathophysiology in HCM: The rapid ejection of blood past a thickened septum creates a negative pressure zone (Venturi effect), which literally "sucks" the anterior mitral valve leaflet into the septum during systole. Guideline Application: This Systolic Anterior Motion (SAM) causes dynamic LVOT obstruction and eccentric Mitral Regurgitation. Treatment relies on negative inotropes (Beta-blockers, non-dihydropyridine CCBs, or Mavacamten) to slow ejection velocity and prevent SAM.
Cross-Examination (5 Q&A):

Q: Is SAM solely caused by the Venturi effect? A: No, structural abnormalities (elongated leaflets, anteriorly displaced papillary muscles) and drag forces also contribute.
Q: What direction does the MR jet go in SAM? A: Posteriorly and laterally.
Q: What happens if you give vasodilators/nitrates? A: Preload and afterload drop, the LV cavity shrinks, velocity increases, and SAM dramatically worsens.
Q: What is the mechanism of Mavacamten? A: Cardiac myosin inhibitor; it reduces excessive actin-myosin cross-bridge formation, lowering contractility.
Q: Does Valsalva increase or decrease the murmur? A: Increases it (decreased venous return -> smaller LV cavity -> worsened obstruction).

3. Mechanism of action of Sacubitril-Valsartan (Neprilysin vs. RAAS).

Response Template: Physiological Principle: Neprilysin is a neutral endopeptidase that degrades natriuretic peptides (NPs) and bradykinin. Inhibiting it increases NPs, promoting vasodilation and natriuresis. Pathophysiology: Neprilysin also degrades Angiotensin II. Blocking neprilysin alone paradoxically increases Angiotensin II, negating the benefits. Guideline Application: Sacubitril (neprilysin inhibitor) must be combined with Valsartan (ARB) to block the RAAS surge. It cannot be combined with an ACE inhibitor due to a synergistic block of bradykinin degradation, leading to life-threatening angioedema.
Cross-Examination (5 Q&A):

Q: What is the mandatory washout period when switching from an ACEi to ARNI? A: 36 hours.
Q: Why is BNP elevated while taking ARNI? A: Sacubitril inhibits the degradation of BNP.
Q: How do you monitor heart failure status in a patient on ARNI? A: Measure NT-proBNP (it is not a substrate for neprilysin).
Q: Is ARNI indicated in HFpEF? A: Guidelines suggest it can be considered, particularly in those with LVEF on the lower end of the preserved spectrum (HFmrEF).
Q: Major side effects of ARNI? A: Hypotension, hyperkalemia, and renal impairment.

4. Why are SGLT2 inhibitors indicated in HF regardless of diabetes status?

Response Template: Physiological Principle: SGLT2 inhibitors (Dapagliflozin, Empagliflozin) promote glycosuria and osmotic diuresis. Pathophysiology in HF: Their benefit is independent of glucose lowering. They reduce interstitial edema without causing intravascular volume depletion, shift myocardial metabolism from fatty acids to efficient ketone bodies, and inhibit the Na+/H+ exchanger (NHE1) in the myocardium, reducing intracellular calcium overload and arrhythmogenesis. Guideline Application: Class 1 recommendation for all symptomatic heart failure (HFrEF, HFmrEF, and HFpEF), reducing mortality and hospitalizations.
Cross-Examination (5 Q&A):

Q: Do SGLT2i activate the sympathetic nervous system like loop diuretics? A: No, they lack sympathetic activation, which is highly protective.
Q: What happens to the hematocrit? A: It rises slightly due to hemoconcentration and increased erythropoietin production.
Q: Major risk factor to warn patients about? A: Euglycemic diabetic ketoacidosis (DKA) and mycotic genital infections.
Q: What is the eGFR cutoff for starting them in HF? A: Generally eGFR > 20 mL/min/1.73m2 (depending on specific drug labels).
Q: Do they cause significant hypoglycemia in non-diabetics? A: No, due to compensatory hepatic gluconeogenesis.

5. What is the "Afterload Mismatch" in severe Aortic Stenosis?

Response Template: Physiological Principle: Wall stress (afterload) is directly proportional to pressure and radius, and inversely proportional to wall thickness (Laplace's Law). Pathophysiology: In severe AS, the LV generates immense pressure to overcome the stenotic valve. Eventually, the wall stress becomes so high that the LV cannot eject fully, and the Ejection Fraction (EF) drops—even though intrinsic myocardial contractility is still normal. Guideline Application: This is "afterload mismatch." If identified (e.g., LFLG AS with contractile reserve), AVR/TAVR immediately removes the afterload, and the EF dramatically recovers.
Cross-Examination (5 Q&A):

Q: How does the LV initially compensate for high afterload? A: Concentric hypertrophy (increases wall thickness to normalize wall stress).
Q: What causes the ultimate failure of this compensation? A: Subendocardial ischemia and myocardial fibrosis.
Q: If intrinsic contractility is truly lost, will AVR restore EF? A: No, replacement in end-stage burnt-out myocardium has higher mortality and less EF recovery.
Q: How does Dobutamine stress echo test this? A: By proving "contractile reserve" (Stroke volume increases > 20%).
Q: What hemodynamics define severe AS? A: Peak velocity > 4 m/s, Mean gradient > 40 mmHg, AVA < 1.0 cm2.

6. Differentiate between systolic and diastolic heart failure (HFpEF vs HFrEF).

Response Template: Physiological Principle: HFrEF is a primary failure of contractility and ejection; HFpEF is a primary failure of active relaxation and passive compliance. Pathophysiology: HFrEF features eccentric hypertrophy, high end-diastolic volumes (EDV), and reduced stroke volume. HFpEF features concentric hypertrophy, normal EDV, but a massively elevated LVEDP for any given volume due to a stiff ventricle (abnormal Titin isoform phosphorylation and fibrosis). Guideline Application: HFrEF has proven mortality-reducing therapies (ARNI, BB, MRA, SGLT2i). HFpEF therapy relies heavily on SGLT2i, diuretics for congestion, and strict comorbidity management (HTN, AFib).
Cross-Examination (5 Q&A):

Q: What is the hallmark of HFpEF on cardiac catheterization? A: Elevated PCWP (>15 mmHg at rest, or >25 mmHg with exercise).
Q: How does the Titin protein differ in HFpEF? A: There is a shift towards the stiffer N2B isoform and hypophosphorylation of Titin.
Q: What is the role of the endothelium in HFpEF? A: Systemic microvascular inflammation leads to reduced NO bioavailability and impaired myocardial relaxation.
Q: What is HFmrEF? A: Heart Failure with mildly reduced EF (41-49%); treated mostly like HFrEF.
Q: Which type relies more on atrial kick? A: HFpEF. Loss of sinus rhythm (AFib) causes precipitous decompensation.

7. What is the significance of the "a" wave in JVP?

Response Template: Physiological Principle: The 'a' wave represents right atrial presystolic contraction, actively pushing blood into the Right Ventricle. Pathophysiology: A prominent 'a' wave indicates the RA is contracting against increased resistance (e.g., Tricuspid Stenosis, Pulmonary Stenosis, or RV Hypertrophy). A "cannon 'a' wave" occurs when the RA contracts against a closed tricuspid valve (AV dissociation). Guideline Application: Absence of an 'a' wave confirms Atrial Fibrillation, mandating stroke risk assessment (CHA2DS2-VASc) and rate/rhythm control.
Cross-Examination (5 Q&A):

Q: When do cannon 'a' waves occur? A: Complete Heart Block, Ventricular Tachycardia, PVCs.
Q: What occurs simultaneously with the 'a' wave in the cardiac cycle? A: The P wave on the ECG and the S4 heart sound.
Q: What follows the 'a' wave in the JVP tracing? A: The 'x' descent (atrial relaxation).
Q: How does severe TR alter the JVP? A: The 'v' wave merges with the 'c' wave, obliterating the 'x' descent (large cv wave).
Q: Can you see an 'a' wave in atrial flutter? A: Yes, you may see rapid flutter waves in the JVP.

8. Explain the pathophysiology of "Low Flow, Low Gradient" AS.

Response Template: Physiological Principle: The transvalvular gradient is highly dependent on flow (Stroke Volume). Pathophysiology: Classical LFLG AS occurs in HFrEF; the weak LV cannot generate a high gradient (>40mmHg) despite a severely stenotic valve (<1.0 cm2). Paradoxical LFLG AS occurs in HFpEF; a small, stiff LV cavity with concentric hypertrophy ejects a low stroke volume (low flow), generating a low gradient despite normal EF (>50%). Guideline Application: Both require intervention if true severe AS is confirmed. Use Dobutamine Stress Echo for classical LFLG to test flow reserve; use CT Calcium Scoring to confirm paradoxical LFLG.
Cross-Examination (5 Q&A):

Q: What defines "Low Flow"? A: Stroke Volume Index (SVI) < 35 mL/m2.
Q: What happens during DSE if it's "Pseudo-severe" AS? A: Stroke volume increases, the valve opens wider (AVA > 1.0 cm2), and the gradient remains low.
Q: What happens during DSE if it's "True severe" AS? A: Stroke volume increases, the valve stays fixed (AVA < 1.0 cm2), and the gradient rises > 40 mmHg.
Q: What if there is no contractile reserve on DSE? A: Proceed to CT Calcium scoring of the aortic valve.
Q: What Agatston score confirms severe AS in men and women? A: > 2000 in men, > 1200 in women.

9. Mechanism of Ivabradine (If channel inhibition).

Response Template: Physiological Principle: The "funny" current (If) in the Sinoatrial (SA) node controls the slope of spontaneous diastolic depolarization, determining heart rate. Pathophysiology: Elevated resting heart rate in HFrEF increases myocardial oxygen demand and decreases diastolic filling time/coronary perfusion. Guideline Application: Ivabradine specifically inhibits the If channel, lowering HR without any negative inotropic effect. Class IIa indication for HFrEF (EF < 35%) in Sinus Rhythm with a resting HR > 70 bpm, despite maximally tolerated beta-blockers.
Cross-Examination (5 Q&A):

Q: Does Ivabradine affect blood pressure? A: No, it has no direct vascular effects.
Q: Can it be used in Atrial Fibrillation? A: No, it works exclusively on the SA node.
Q: What is a unique ocular side effect? A: Phosphenes (transient luminous phenomena) due to inhibition of the Ih current in the retina.
Q: Does it improve mortality? A: It primarily reduces heart failure hospitalizations (SHIFT trial).
Q: Can it be used in acute decompensated HF? A: No, the patient must be stable.

10. What is the role of the "Heart Team" in HF management?

Response Template: Clinical Principle: Advanced heart failure involves complex, intersecting pathologies that exceed single-physician expertise. Guideline Application: The ESC/ACC mandate a multidisciplinary "Heart Team" (HF cardiologists, cardiothoracic surgeons, interventionalists, EP, palliative care, and specialist nurses) to evaluate patients for advanced therapies (OHT, LVAD, TEER, or complex PCI) when they reach Stage D HF (INTERMACS profiles). It ensures shared decision-making, patient-centered care, and optimal procedural timing.
Cross-Examination (5 Q&A):

Q: What is the "I NEED HELP" mnemonic? A: Criteria for advanced HF referral (Inotropes, NYHA III/IV, End-organ dysfunction, EF <20%, Defibrillator shocks, Hospitalizations, Edema despite diuretics, Low BP, Prognostic meds intolerant).
Q: What is INTERMACS Profile 1? A: Critical cardiogenic shock ("Crash and burn").
Q: What is INTERMACS Profile 4? A: Resting symptoms on oral therapy at home ("Frequent flyer").
Q: When is palliative care integrated? A: Early in advanced HF, not just at the end of life.
Q: What is Destination Therapy (DT)? A: LVAD placement for a patient who is permanently ineligible for transplant.

11. How does chronic pressure overload lead to RV failure?

Response Template: Physiological Principle: The RV is thin-walled and highly compliant, anatomically designed for volume loading against low pulmonary resistance, not pressure work. Pathophysiology: In chronic pressure overload (e.g., PAH, Cor Pulmonale), the RV undergoes concentric hypertrophy. This increases wall stress and oxygen demand. Because capillary angiogenesis fails to match myocyte hypertrophy (capillary mismatch), the RV suffers subendocardial ischemia, leading to progressive dilation, tricuspid annular stretching (severe TR), and ultimate pump failure. Guideline Application: Treatment requires aggressively lowering Pulmonary Vascular Resistance (PVR) and offloading volume (diuretics) to prevent the lethal spiral of RV ischemia.
Cross-Examination (5 Q&A):

Q: How does RV failure affect the LV? A: The interventricular septum bows into the LV during diastole (D-shape), reducing LV filling (ventricular interdependence).
Q: When does coronary perfusion to the RV normally occur? A: Throughout both systole and diastole (unlike the LV, which is diastole-only).
Q: What happens to RV coronary perfusion in severe PHTN? A: As RV systolic pressure approaches aortic pressure, systolic coronary flow ceases, causing ischemia.
Q: What is the significance of Tricuspid Regurgitation? A: It causes a volume overload on top of the pressure overload, accelerating failure.
Q: Does the RV remodel differently than the LV? A: Yes, it shifts from a crescentic shape to a spherical shape.

12. Define "Cardiorenal Syndrome" Type 1 vs Type 2.

Response Template: Physiological Principle: The heart and kidneys are hemodynamically and neurohormonally linked. Pathophysiology: Type 1 (Acute Cardiorenal) is an acute worsening of cardiac function (e.g., ADHF, cardiogenic shock) leading to Acute Kidney Injury (AKI). It is driven largely by severe venous congestion (backward failure) increasing renal interstitial pressure and reducing GFR, more so than low cardiac output. Type 2 (Chronic Cardiorenal) is chronic heart failure leading to progressive Chronic Kidney Disease (CKD) via chronic hypoperfusion and RAAS/SNS hyperactivation. Guideline Application: Congestion is the main enemy; aggressive decongestion (often requiring sequential nephron blockade) improves GFR in Type 1, despite initial transient bumps in creatinine.
Cross-Examination (5 Q&A):

Q: What is Type 3 Cardiorenal Syndrome? A: Acute worsening of kidney function (e.g., contrast nephropathy) causing acute heart failure.
Q: What is Type 4? A: Chronic Kidney Disease causing chronic cardiac dysfunction (LVH, CAD, HF).
Q: What is Type 5? A: Systemic conditions (e.g., Sepsis, Amyloidosis, SLE) causing simultaneous failure of both organs.
Q: If creatinine rises 20% after starting an ACE inhibitor in HF, what is the action? A: Observe; a mild bump is expected due to efferent arteriolar vasodilation and reflects prognostic benefit.
Q: What central pressure directly correlates with worsening GFR in HF? A: Elevated Central Venous Pressure (CVP).

13. Why does Digoxin have a narrow therapeutic index in HF?

Response Template: Physiological Principle: Digoxin binds to and inhibits the Na+/K+ ATPase pump on the myocardial membrane, increasing intracellular sodium, which reverses the Na+/Ca2+ exchanger, increasing intracellular calcium (positive inotropy) while increasing vagal tone. Pathophysiology: The binding affinity of Digoxin to the pump is highly sensitive to serum potassium levels. Hypokalemia (common with loop diuretics in HF) leaves the binding sites exposed, leading to massive digoxin binding, severe calcium overload, and triggered arrhythmias (Delayed After-Depolarizations). Guideline Application: Used rarely today; Class IIb indication for rate control in AFib with HFrEF, or in severe HFrEF for symptom control. Target serum levels must be kept strictly low (0.5 - 0.9 ng/mL).
Cross-Examination (5 Q&A):

Q: Does Digoxin improve mortality in HFrEF? A: No, it only reduces hospitalizations (DIG trial).
Q: What is the most classic arrhythmia in digoxin toxicity? A: Bidirectional Ventricular Tachycardia.
Q: How does hypercalcemia affect digoxin? A: It exacerbates toxicity (increases intracellular calcium further).
Q: What is the ECG sign of "Digoxin effect" (not toxicity)? A: Downsloping ST depression (Salvador Dali mustache).
Q: What is the definitive treatment for life-threatening toxicity? A: Digoxin-specific Fab fragments (DigiBind).

14. What are the "Class 1" indications for CRT in HFrEF?

Response Template: Physiological Principle: LBBB causes delayed, dyssynchronous contraction of the lateral LV wall compared to the septum. This mechanical inefficiency reduces EF and promotes adverse remodeling. Guideline Application (ESC/ACC): Cardiac Resynchronization Therapy (CRT) places a pacing lead in a coronary sinus branch to pace the lateral wall simultaneously with the RV. A Class I indication requires: Symptomatic HF (NYHA II-IV) on optimal GDMT, LVEF ≤ 35%, Sinus Rhythm, LBBB morphology, and a QRS duration ≥ 150 ms.
Cross-Examination (5 Q&A):

Q: What if the QRS is 130-149 ms with LBBB? A: It is a Class IIa recommendation.
Q: What if the patient has a non-LBBB pattern (e.g., RBBB)? A: Class IIa if QRS ≥ 150 ms; Class IIb or III if QRS < 150 ms (less evidence of benefit).
Q: Does CRT improve mortality? A: Yes, it reduces mortality, hospitalizations, and reverses remodeling.
Q: Can CRT be done in Atrial Fibrillation? A: Yes (Class IIa), provided near 100% biventricular pacing can be achieved (often requires AV node ablation).
Q: What is a major cause of non-response to CRT? A: Suboptimal LV lead placement (e.g., in an anterior vein or an area of dense scar).

15. Explain the Starling-resistance in cardiac tamponade.

Response Template: Physiological Principle: The heart operates within a rigid pericardial space. Pathophysiology: As pericardial fluid accumulates rapidly, intrapericardial pressure rises until it exceeds the diastolic filling pressures of the right and left heart. The transmural pressure gradient (inside vs. outside the chamber) drops to zero. The chambers collapse during diastole, and stroke volume plummets. Guideline Application: Because total cardiac volume is fixed, inspiration (which draws blood into the RV) forcefully bows the septum into the LV. This severe ventricular interdependence drops LV stroke volume dramatically, manifesting clinically as Pulsus Paradoxus. Immediate pericardiocentesis restores transmural pressure.
Cross-Examination (5 Q&A):

Q: Which chamber collapses first on Echocardiography? A: The Right Atrium (systolic collapse), as it has the lowest pressure.
Q: What is the most specific Echo sign for clinical tamponade? A: Right Ventricular early diastolic collapse.
Q: What happens to the 'y' descent on the JVP? A: It is absent or blunted (the ventricles cannot fill rapidly in early diastole).
Q: Is Pulsus Paradoxus specific only to tamponade? A: No, it is also seen in severe asthma/COPD due to negative intrathoracic pressure swings.
Q: What hemodynamic state equalizes in tamponade? A: Diastolic pressures equalize across all four chambers (RA = RVEDP = LA = LVEDP).

16. How does the "square root sign" occur in constrictive pericarditis?

Response Template: Physiological Principle: In constrictive pericarditis, the heart is encased in a rigid, fibrotic, or calcified shell. Pathophysiology: Unlike tamponade (where filling is impeded throughout diastole), in constriction, early diastolic filling is unhindered because the ventricular volume is still smaller than the rigid pericardial shell. Blood rushes in rapidly (creating a steep 'y' descent). Mid-way through diastole, the ventricle hits the rigid pericardium, and filling comes to an abrupt, violent halt. Guideline Application: On right heart catheterization, this manifests as the "dip and plateau" or "square root sign" in the ventricular pressure trace. It is diagnostic for constriction and indicates the need for surgical pericardiectomy.
Cross-Examination (5 Q&A):

Q: What is the clinical equivalent of the abrupt halt in filling? A: The Pericardial Knock (an early diastolic sound).
Q: What happens to the 'y' descent in the JVP? A: It becomes very rapid and deep (Friedreich's sign).
Q: What is Kussmaul's sign? A: A paradoxical rise in JVP during inspiration (seen in constriction, NOT tamponade).
Q: How do LV and RV pressures behave during respiration in constriction? A: Discordance. (RV pressure rises while LV pressure falls during inspiration).
Q: How does this differ from Restrictive Cardiomyopathy on cath? A: Restriction lacks respiratory discordance (pressures are concordant).

17. Mechanism of action of Epoprostenol in PAH.

Response Template: Physiological Principle: Prostacyclin (PGI2) is produced by healthy pulmonary endothelium. It binds to IP receptors on vascular smooth muscle, increasing cAMP. Pathophysiology: In Pulmonary Arterial Hypertension (PAH), prostacyclin synthase is profoundly deficient, leading to severe vasoconstriction, platelet aggregation, and unchecked smooth muscle proliferation. Guideline Application: Epoprostenol is synthetic prostacyclin. It provides potent, immediate pulmonary vasodilation, inhibits platelet aggregation, and prevents vascular remodeling. It is a Class 1 indication for high-risk (WHO FC IV) PAH patients, delivered via continuous IV infusion due to its half-life of 3-5 minutes.
Cross-Examination (5 Q&A):

Q: Why must it be given via a central line? A: Severe local tissue damage/pain via peripheral IV, and the extremely short half-life requires uninterrupted delivery.
Q: What happens if the pump stops abruptly? A: Fatal rebound pulmonary hypertension and right heart failure.
Q: What are common dose-dependent side effects? A: Jaw pain, flushing, diarrhea, and severe foot/leg pain.
Q: Does it improve survival? A: Yes, it is the first therapy proven to improve survival in severe PAH.
Q: Name an oral prostacyclin pathway agonist? A: Selexipag (IP receptor agonist).

18. Define "Pre-capillary" vs "Post-capillary" Pulmonary Hypertension.

Response Template: Physiological Principle: Pulmonary hypertension can originate from the pulmonary arteries (pre-capillary) or back-pressure from the left heart (post-capillary). Guideline Application (2022/2025 Updates): Pre-capillary PH (e.g., PAH, Group 1) is defined hemodynamically by a mean Pulmonary Artery Pressure (mPAP) > 20 mmHg, a Pulmonary Artery Wedge Pressure (PAWP) ≤ 15 mmHg, and a Pulmonary Vascular Resistance (PVR) > 2 Wood Units (WU). Isolated Post-capillary PH (e.g., Left Heart Disease, Group 2) has mPAP > 20 mmHg, PAWP > 15 mmHg, but a normal PVR (≤ 2 WU).
Cross-Examination (5 Q&A):

Q: What is Combined Pre- and Post-Capillary PH (CpcPH)? A: mPAP > 20, PAWP > 15, and PVR > 2 WU. (Left heart disease that has caused permanent pulmonary vascular remodeling).
Q: How was the definition of mPAP changed recently? A: It was lowered from ≥ 25 mmHg to > 20 mmHg.
Q: How was the PVR definition changed? A: Lowered from ≥ 3 WU to > 2 WU.
Q: Why is PAWP used? A: When the balloon is inflated, it creates a static column of blood reflecting Left Atrial Pressure.
Q: Can you give PAH-specific drugs (like PDE5 inhibitors) to Group 2 Post-capillary PH patients? A: No, it is generally contraindicated as it can precipitate acute pulmonary edema by flooding a stiff left heart.

19. Why does BNP rise in heart failure?

Response Template: Physiological Principle: B-type Natriuretic Peptide (BNP) is a counter-regulatory hormone synthesized primarily by the ventricular myocardium. Pathophysiology: In response to increased ventricular wall stretch, volume overload, and wall stress, the BNP gene is upregulated. The pro-hormone (proBNP) is cleaved into active BNP (promotes vasodilation, natriuresis, and inhibits RAAS/SNS) and inactive NT-proBNP. Guideline Application: It is the gold standard biomarker for diagnosing heart failure, guiding prognosis, and differentiating cardiac from pulmonary causes of dyspnea in the emergency department.
Cross-Examination (5 Q&A):

Q: What degrades active BNP? A: Neprilysin (which is why Sacubitril elevates BNP levels).
Q: Which is cleared renally: BNP or NT-proBNP? A: NT-proBNP is almost exclusively renally cleared, making it highly sensitive to CKD.
Q: Does obesity increase or decrease BNP levels? A: Obesity falsely decreases BNP levels (due to increased clearance by adipose tissue clearance receptors).
Q: Does Atrial Fibrillation affect it? A: Yes, AFib elevates BNP independent of heart failure.
Q: Is the half-life of BNP or NT-proBNP longer? A: NT-proBNP is much longer (1-2 hours) compared to BNP (20 minutes), making it a more stable diagnostic marker.

20. What are the predictors of "Reverse Remodeling" in DCM?

Response Template: Physiological Principle: Dilated Cardiomyopathy (DCM) features eccentric hypertrophy and spherical remodeling. Pathophysiology: With removal of the toxic insult or aggressive offloading of the LV, the myocardium has the plastic capacity to shrink its volumes and restore a more elliptical geometry, a process known as Reverse Remodeling. Guideline Application: GDMT (ARNI, Beta-blockers, MRA, SGLT2i) and CRT powerfully drive this. Positive predictors include: Non-ischemic etiology (e.g., Tachycardia-induced, Peripartum), female gender, short duration of heart failure, lack of severe fibrosis on CMR (no LGE), and left bundle branch block resolution via CRT.
Cross-Examination (5 Q&A):

Q: Can ischemic cardiomyopathy undergo reverse remodeling? A: Yes, but to a lesser extent, as dead scar tissue (transmural infarct) cannot recover.
Q: Which specific drug class has the most profound effect on reversing LV geometry? A: Beta-blockers (prolong diastole, reduce catecholamine toxicity).
Q: If LVEF recovers to >50%, can the patient stop their GDMT? A: No, the TRED-HF trial showed that withdrawing therapy leads to rapid relapse; this is "remission," not a cure.
Q: What happens to the mitral valve during reverse remodeling? A: The LV cavity shrinks, papillary muscles realign, and functional Mitral Regurgitation improves or resolves.
Q: What is the ideal time frame to assess reverse remodeling after optimizing medical therapy? A: Typically 3 to 6 months.

II. VALVULAR HEART DISEASE (20 QUESTIONS)

1. Pathophysiology of the "Opening Snap" in MS.

Response Template: Physiological Principle: Normal mitral valves open silently. In Rheumatic MS, the commissures are fused but the leaflets (initially) remain pliable. Pathophysiology: As LV pressure falls below LA pressure in early diastole, the fused valve "parachutes" into the LV. The sudden tensing of the fused leaflets and chordae generates a high-pitched Opening Snap (OS). Guideline Application: The presence of an OS indicates a pliable, non-calcified valve, which is a highly favorable prognostic sign for Percutaneous Transvenous Mitral Commissurotomy (PTMC/BMV). Loss of the OS implies heavy calcification, pushing the decision toward surgical valve replacement.
Cross-Examination (5 Q&A):

Q: How does the A2-OS interval correlate with severity? A: The more severe the MS, the higher the LA pressure, causing the valve to snap open earlier (shorter A2-OS interval).
Q: Where is the OS heard best? A: Between the apex and the left lower sternal border.
Q: How do you differentiate an OS from a third heart sound (S3)? A: OS is early, high-pitched, and sharp (heard with the diaphragm); S3 is later, low-pitched, and dull (heard with the bell).
Q: What happens to the OS if the valve becomes heavily calcified? A: It disappears because the leaflets lose their mobility.
Q: What is the timing in the cardiac cycle? A: Early diastole, immediately following S2.

2. ESC 2025 criteria for severe AS (Vmax, Mean gradient, AVA).

Response Template: Physiological Principle: The degree of obstruction dictates the pressure gradient required to maintain stroke volume. Pathophysiology: As the orifice narrows, blood velocity must increase (Continuity principle). Guideline Application (ESC 2025): Severe Aortic Stenosis is defined by: Peak velocity (Vmax) >= 4.0 m/s, Mean pressure gradient >= 40 mmHg, and an Aortic Valve Area (AVA) <= 1.0 cm2 (or indexed AVA <= 0.6 cm2/m2). These cutoffs trigger intervention (SAVR or TAVI) in symptomatic patients.
Cross-Examination (5 Q&A):

Q: What defines a "Low-Flow" state? A: Stroke Volume Index (SVI) <= 35 mL/m2.
Q: What is the Dimensionless Index (DI) and its severe cutoff? A: Ratio of LVOT VTI to Aortic Valve VTI; a DI < 0.25 indicates severe AS.
Q: Why use the Dimensionless Index? A: It removes the LVOT area calculation, eliminating the squaring of the LVOT radius error.
Q: If Vmax is 3.5 m/s but AVA is 0.8 cm2, what is the diagnosis? A: Discordant grading (Low-Flow, Low-Gradient AS).
Q: Which parameter is least flow-dependent? A: Aortic Valve Area (though it can vary slightly, it is more stable than gradients).

3. Why is PTMC contraindicated in significant MR?

Response Template: Physiological Principle: The left atrium in MS acts as a high-pressure reservoir but has adapted to forward obstruction. Pathophysiology: The PTMC balloon forcefully tears the fused commissures to relieve stenosis. If moderate (Grade 2+) Mitral Regurgitation already exists, tearing the commissures will abruptly worsen the regurgitation to severe. Guideline Application: An acute volume overload (severe MR) superimposed on a non-compliant, pressure-overloaded LA causes massive backward failure (fulminant pulmonary edema). Therefore, > Grade 2 MR is an absolute contraindication to PTMC; these patients require Surgical Mitral Valve Replacement.
Cross-Examination (5 Q&A):

Q: What is another absolute contraindication to PTMC? A: Left Atrial Appendage (LAA) thrombus.
Q: What is the mechanism of the Inoue balloon? A: Distal inflation anchors in the LV, proximal inflation anchors in the LA, and middle inflation tears the commissures.
Q: If the Wilkins score is > 8, what is the risk? A: High risk of suboptimal opening or causing severe MR.
Q: How is the patient managed if LAA clot is found? A: Anticoagulation for 3-4 weeks, then repeat TEE.
Q: What defines a successful PTMC? A: MVA > 1.5 cm2 and no more than moderate MR.

4. Explain the mechanism of "Acute Aortic Regurgitation" (why is it lethal?).

Response Template: Physiological Principle: The LV requires time to undergo eccentric hypertrophy to handle volume overloads. Pathophysiology: In Acute AR (e.g., infective endocarditis, aortic dissection), a massive volume of blood dumps backward into a normal-sized, stiff, non-compliant LV. The Left Ventricular End-Diastolic Pressure (LVEDP) skyrockets instantaneously, exceeding Left Atrial pressure and causing premature closure of the mitral valve. Guideline Application: This results in catastrophic pulmonary edema and cardiogenic shock. Urgent surgical intervention is mandatory. Intra-aortic balloon pumps (IABP) are strictly contraindicated as they worsen the regurgitation.
Cross-Examination (5 Q&A):

Q: What happens to the pulse pressure in acute AR? A: It is normal or narrow (unlike the wide pulse pressure of chronic AR) because stroke volume is low.
Q: Why does the mitral valve close prematurely? A: LVEDP rapidly rises higher than LA pressure during mid-diastole.
Q: Why is tachycardia protective in acute AR? A: It shortens diastole, reducing the time for regurgitant backward flow.
Q: What is the role of vasodilators (Nitroprusside)? A: Used as a temporary bridge to reduce afterload and improve forward flow until surgery.
Q: How does the murmur differ from chronic AR? A: It is short and low-pitched (due to rapid equalization of aortic and LV diastolic pressures).

5. What is the "Wilkins Score" and what does it predict?

Response Template: Physiological Principle: The success of balloon commissurotomy depends on the pliability of the valve apparatus. Pathophysiology: Thick, calcified, immobile leaflets with severe subvalvular fusion will not split cleanly and are prone to tearing (causing MR). Guideline Application: The Wilkins Score evaluates four echocardiographic parameters: Leaflet Mobility, Valve Thickening, Calcification, and Subvalvular Thickening (each scored 1-4, max 16). A score <= 8 is ideal for PTMC. A score > 8 predicts a lower success rate and higher complication rate.
Cross-Examination (5 Q&A):

Q: Which component is the strongest predictor of PTMC failure? A: Severe subvalvular thickening/fusion and heavy calcification.
Q: What is the Cormier score? A: An alternative French scoring system emphasizing calcification and subvalvular disease.
Q: Can you do PTMC in a pregnant patient with severe MS? A: Yes, it is the treatment of choice in the 2nd trimester if medical therapy fails.
Q: If a patient has a Wilkins score of 10 but is prohibitive surgical risk, what is done? A: PTMC can still be attempted as palliative therapy.
Q: Does the Wilkins score predict long-term restenosis? A: Yes, higher scores correlate with faster rates of restenosis.

6. Describe the "Myxomatous degeneration" of the mitral valve.

Response Template: Physiological Principle: The normal mitral leaflet has three layers: Fibrosa (strength), Spongiosa (shock absorption), and Ventricularis. Pathophysiology: In myxomatous degeneration (Barlow's disease), there is pathological proliferation of the spongiosa layer with excess glycosaminoglycans (GAGs). The fibrosa weakens, causing the leaflets to become thick, redundant, and structurally incompetent, leading to prolapse into the LA during systole. Guideline Application: This is the most common cause of primary organic MR. Guidelines strongly favor early surgical Edge-to-Edge repair or Chordal replacement (rather than valve replacement) in specialized Heart Valve Centers.
Cross-Examination (5 Q&A):

Q: What genetic connective tissue disorders are associated? A: Marfan syndrome and Ehlers-Danlos syndrome.
Q: What is the classic auscultatory finding? A: A mid-systolic click followed by a late systolic murmur.
Q: What causes the mid-systolic click? A: The sudden tensing of the elongated chordae tendineae as the leaflet prolapses.
Q: Differentiate Barlow's disease from Fibroelastic Deficiency (FED)? A: Barlow's has diffuse, thickened, redundant tissue; FED has thin leaflets with isolated ruptured chordae in the elderly.
Q: How do standing or Valsalva affect the click/murmur? A: Decreased LV volume causes the prolapse to happen earlier (click moves closer to S1, murmur becomes longer).

7. Why does Mitral Regurgitation cause LV dilatation but not severe hypertrophy?

Response Template: Physiological Principle: Laplace’s Law states wall stress = (Pressure x radius) / (2 x wall thickness). Hypertrophy is primarily a response to pressure overload (high wall stress). Pathophysiology: In MR, the LV ejects blood into two pathways: the high-pressure aorta and the low-pressure left atrium. Because a large volume vents into the low-pressure LA, the LV afterload is actually normal or even reduced. Therefore, there is no strong pressure stimulus for concentric hypertrophy. Instead, the volume overload causes sarcomeres to replicate in series, resulting in massive eccentric LV dilatation. Guideline Application: Because afterload is low, the Ejection Fraction (EF) is falsely elevated. An EF of 60% in severe MR actually represents significant LV dysfunction, triggering surgical intervention.
Cross-Examination (5 Q&A):

Q: What is the surgical EF threshold for asymptomatic severe MR? A: EF <= 60%.
Q: What happens to the EF immediately after mitral valve surgery? A: It drops, because the low-pressure "pop-off" to the LA is removed, and the LV must now eject entirely against systemic afterload.
Q: What is the surgical threshold for LV size in asymptomatic MR? A: LV End-Systolic Dimension (LVESD) >= 40 mm.
Q: How does this differ from Aortic Regurgitation remodeling? A: AR involves both volume overload AND pressure overload (ejecting massive stroke volume into the aorta), so the LV undergoes both massive dilatation and significant hypertrophy.
Q: What wave is prominent on the LA pressure tracing in MR? A: A giant 'v' wave during systole.

8. Role of Dobutamine stress echo in "Pseudosevere" AS.

Response Template: Physiological Principle: Aortic valve area (AVA) is flow-dependent; a weak ventricle generating low flow may fail to push open a moderately stiff valve, falsely mimicking severe AS. Pathophysiology: Low-Dose Dobutamine Stress Echo (DSE) increases myocardial contractility (stroke volume). If the valve is truly severely stenotic, increasing flow will cause the pressure gradient to rise > 40 mmHg while the AVA remains fixed (<1.0 cm2). If it is "Pseudosevere" (moderate AS with low EF), the increased flow will force the valve open (AVA > 1.0 cm2) and the gradient will remain low. Guideline Application: DSE is essential for Classical Low-Flow, Low-Gradient AS (HFrEF) to distinguish true severe AS (needs AVR) from pseudosevere AS (needs HF medical therapy).
Cross-Examination (5 Q&A):

Q: What defines "contractile reserve" (flow reserve) on DSE? A: An increase in stroke volume by > 20%.
Q: What if the patient has no contractile reserve? A: The DSE is inconclusive; surgical risk is very high.
Q: How do you diagnose severe AS if there is no contractile reserve? A: Perform a non-contrast CT Calcium Score of the aortic valve.
Q: What is the calcium score threshold for severe AS in men? A: > 2000 Agatston units.
Q: What is the threshold for women? A: > 1200 Agatston units.

9. Indications for surgical intervention in Asymptomatic severe MR.

Response Template: Physiological Principle: Chronic volume overload causes insidious myocardial damage (fibrosis and myocyte loss) that becomes irreversible before symptoms occur. Guideline Application (ESC/ACC 2025): To prevent irreversible heart failure, surgery (preferably repair) is indicated in asymptomatic severe primary MR if the LV begins to decompensate: EF <= 60%, or LVESD >= 40 mm. Additionally, surgery is recommended if there is new-onset Atrial Fibrillation or severe pulmonary hypertension (PASP > 50 mmHg at rest). A "watchful waiting" approach is only valid if the patient is closely monitored and repair probability is low.
Cross-Examination (5 Q&A):

Q: Why is an EF of 60% considered impaired in MR? A: MR unloads the LV into the LA; a normal LV in MR should have an EF > 65-70%.
Q: What is the role of BNP in asymptomatic MR? A: Serial elevations in BNP can prompt earlier intervention.
Q: If the patient has normal LV size/function (EF > 60%, ESD < 40mm), can they get surgery? A: Yes (Class IIa), if the likelihood of a successful repair is > 95% with < 1% mortality at a Heart Valve Center.
Q: What is the preferred surgical approach? A: Mitral Valve Repair (preserves chordal apparatus and LV geometry) over Replacement.
Q: What is the role of exercise stress echo? A: Unmasks symptoms or shows a massive rise in pulmonary pressures with exertion.

10. Differentiate between organic and functional TR.

Response Template: Physiological Principle: Valvular incompetence can arise from the leaflets themselves (organic/primary) or from the supporting geometry (functional/secondary). Pathophysiology: Organic TR involves destruction or tethering of the leaflets/chordae (e.g., Rheumatic, Carcinoid, Endocarditis, Pacemaker lead impingement, Ebstein anomaly). Functional TR has anatomically normal leaflets; the regurgitation occurs because RV dilation (from PAH, Left heart failure) or RA dilation (from chronic AFib) stretches the tricuspid annulus, pulling the leaflets apart. Guideline Application: Functional TR (80% of cases) is treated by managing the primary left-sided disease/PAH and diuretics. Concomitant Tricuspid Annuloplasty is recommended during left-sided valve surgery if the tricuspid annulus is dilated (>40 mm or >21 mm/m2) to prevent future severe TR.
Cross-Examination (5 Q&A):

Q: What is "atrial functional TR"? A: Severe TR driven purely by massive right atrial and annular dilation from long-standing Atrial Fibrillation, with a normal RV.
Q: How does Carcinoid syndrome affect the TV? A: Plaque deposition causes thick, retracted, fixed leaflets stuck in the open position.
Q: What is the physical sign of severe TR on the JVP? A: Large systolic 'cv' wave (merging of c and v waves).
Q: What is Carvallo's sign? A: The pansystolic murmur of TR increases in intensity during inspiration.
Q: What transcatheter options exist for severe symptomatic TR? A: Transcatheter Edge-to-Edge Repair (TriClip) or transcatheter valve replacement (EVOQUE) are emerging therapies.

11. How does Aortic Root dilatation cause AR?

Response Template: Physiological Principle: Aortic valve competence relies on the precise geometric apposition (coaptation) of the three cusps in the center of the orifice during diastole. Pathophysiology: In conditions causing annuloaortic ectasia (e.g., Marfan syndrome, Bicuspid Aortic Valve aortopathy, severe hypertension), the aortic root and sinotubular junction progressively dilate. This outward pulling stretches the commissures apart, creating a central gap where the anatomically normal leaflets can no longer meet. Guideline Application: This causes a central regurgitant jet. Surgical management requires a valve-sparing aortic root replacement (David procedure) or a composite root-and-valve graft (Bentall procedure) depending on leaflet health and root diameter (>50-55 mm).
Cross-Examination (5 Q&A):

Q: What is the direction of the AR jet in root dilation? A: Typically a central jet.
Q: What is the direction of the AR jet in primary leaflet disease (e.g., prolapse, endocarditis)? A: Typically an eccentric jet directed toward the anterior mitral leaflet or septum.
Q: What is the David procedure? A: The dilated aortic root is replaced with a Dacron tube graft, and the native aortic valve is reimplanted inside it (Valve-sparing).
Q: What is the Bentall procedure? A: Replacement of both the aortic valve and root with a composite graft, requiring reimplantation of the coronary buttons.
Q: In Marfan syndrome, at what root size is prophylactic surgery indicated? A: >= 50 mm (or >= 45 mm with risk factors like family history of dissection).

12. Why is the "A2-OS interval" shorter in severe MS?

Response Template: Physiological Principle: The Opening Snap (OS) occurs when the fused mitral valve is forced open by the pressure gradient between the LA and LV in early diastole. Pathophysiology: Following aortic valve closure (A2), LV pressure drops rapidly during isovolumic relaxation. In mild MS, LA pressure is relatively low, so the LV pressure must drop significantly (taking more time) before LA pressure forces the valve open (Long A2-OS). In severe MS, the LA pressure is massively elevated, so the LV pressure drops below LA pressure almost immediately after A2. Guideline Application: A short A2-OS interval (< 8-10 ms) is a classic bedside physical exam sign of severe, high-pressure MS, correlating with the need for intervention.
Cross-Examination (5 Q&A):

Q: What is the normal duration of the A2-OS interval in mild MS? A: > 100-120 ms.
Q: How does murmur duration relate to MS severity? A: The longer the diastolic rumble lasts into diastole, the more severe the stenosis (indicates the gradient persists throughout diastole).
Q: Does the loudness of the OS correlate with severity? A: No, loudness indicates leaflet pliability, not severity.
Q: What happens to the interval if systemic blood pressure increases? A: A2 occurs earlier (LV has to overcome higher afterload), artificially widening the interval.
Q: What happens if the patient develops severe Pulmonary Hypertension? A: P2 becomes very loud and closely follows A2, making it difficult to distinguish from the OS.

13. Mechanism of hemolysis in prosthetic valves.

Response Template: Physiological Principle: Red blood cells (RBCs) can withstand physiological shear stress, but supraphysiologic turbulence and mechanical impact cause membrane rupture (intravascular hemolysis). Pathophysiology: In mechanical valves, RBCs are physically crushed by the hinges and closing occluders. More severely, high-velocity turbulent jets squeezing through a Paravalvular Leak (PVL)—a gap between the sewing ring and native tissue—create massive shear forces that shred RBCs. Guideline Application: Presentation includes anemia, dark urine, elevated LDH, low haptoglobin, and schistocytes. A significant PVL causing intractable hemolysis or heart failure is an indication for transcatheter plug closure or surgical redo.
Cross-Examination (5 Q&A):

Q: Which type of valve is most associated with hemolysis? A: Mechanical valves, specifically in the setting of paravalvular leak.
Q: What is a schistocyte? A: A fragmented red blood cell ("helmet cell") seen on a peripheral blood smear.
Q: What happens to the haptoglobin level? A: It drops to near zero as it binds to the massive amounts of free hemoglobin released into the plasma.
Q: How is paravalvular leak evaluated? A: Transesophageal Echocardiography (TEE) with 3D color Doppler.
Q: Do bioprosthetic (tissue) valves cause hemolysis? A: Rarely, unless there is a severe paravalvular leak or structural failure (leaflet tear).

14. ESC 2025 guidelines for Anticoagulation in Mechanical Valves.

Response Template: Physiological Principle: Mechanical surfaces (pyrolytic carbon) strongly activate the contact pathway (intrinsic cascade) of coagulation, leading to massive, rapid thrombosis if uninhibited. Guideline Application: Lifelong Vitamin K Antagonists (VKA/Warfarin) are the ONLY approved oral anticoagulants for mechanical valves. Direct Oral Anticoagulants (DOACs/NOACs) are absolutely contraindicated as the RE-ALIGN trial proved they cause excess valve thrombosis and bleeding. The target INR depends on the valve position and patient risk factors: 2.5 for a standard aortic valve, and 3.0 for a mitral valve or an aortic valve with high-risk features (AFib, prior stroke, LV dysfunction).
Cross-Examination (5 Q&A):

Q: What happens if a patient on a mechanical valve gets pregnant? A: Warfarin is teratogenic in the 1st trimester. Switch to LMWH (with strict anti-Xa monitoring) or UFH for the 1st trimester, resume Warfarin in the 2nd/3rd, and switch back to heparin before delivery. Alternatively, if Warfarin dose is < 5mg/day, it may be continued throughout based on risk tolerance.
Q: How do you manage anticoagulation for a dental extraction? A: Do not stop the VKA if the INR is in the therapeutic range; use local hemostatic measures.
Q: When is "bridging" with Heparin required for major surgery? A: Essential for mechanical mitral valves or high-risk mechanical aortic valves when VKA is stopped.
Q: Does a bioprosthetic valve require long-term anticoagulation? A: No, unless they have another indication like Atrial Fibrillation. (Typically just low-dose aspirin after the first 3 months).
Q: What is the PROACT trial? A: Investigating lower INR targets (1.5-2.0) for newer generation mechanical aortic valves (On-X valve).

15. What is the "Erb’s point" and why is it used in AR?

Response Template: Physiological Principle: Sound is best transmitted in the direction of blood flow. Pathophysiology: In primary valvular Aortic Regurgitation (e.g., bicuspid valve, endocarditis), the high-velocity diastolic jet regurgitates from the aorta backward into the left ventricle, angling toward the left lower sternum. Clinical Application: Erb’s point is located at the 3rd intercostal space on the left sternal border. It represents the prime acoustic window where the high-pitched, blowing, decrescendo early diastolic murmur of valvular AR is loudest.
Cross-Examination (5 Q&A):

Q: How do you best elicit this murmur? A: Have the patient sit up, lean forward, exhale completely, and hold their breath. Use the diaphragm of the stethoscope.
Q: If the AR murmur is loudest at the right upper sternal border, what is the likely cause? A: Aortic root dilation (e.g., Marfan, dissection), which alters the jet direction to the right.
Q: What is the Cole-Cecil murmur? A: The AR murmur heard radiating all the way down to the left axilla.
Q: Why is the murmur decrescendo? A: As diastole progresses, the pressure gradient between the aorta and the LV drops, reducing jet velocity and sound.
Q: Is Erb's point useful for Aortic Stenosis? A: AS is usually best heard at the 2nd right intercostal space, radiating to the carotids.

16. Pathophysiology of "Mid-diastolic rumble" in severe AR (Austin Flint).

Response Template: Physiological Principle: Two streams of blood enter the LV simultaneously in diastole during severe AR: normal forward flow from the LA, and abnormal backward flow from the aorta. Pathophysiology: The massive, high-velocity regurgitant jet from the aorta strikes the anterior leaflet of the mitral valve, pushing it into a partially closed position. When the LA tries to empty normal blood volume past this partially closed leaflet, it creates turbulence. Clinical Application: This creates a functional, relative mitral stenosis, generating a low-pitched, mid-to-late diastolic rumble at the apex known as the Austin Flint murmur. It is a sign of severe AR and does not indicate true mitral valve disease.
Cross-Examination (5 Q&A):

Q: How do you distinguish the Austin Flint murmur from true rheumatic Mitral Stenosis at the bedside? A: True MS has a loud S1 and an Opening Snap. Austin Flint has a soft/normal S1 and NO opening snap.
Q: How does Amyl Nitrite (a vasodilator) affect these murmurs? A: Amyl Nitrite drops afterload. AR (and the Austin Flint murmur) will decrease. True MS will increase (due to reflex tachycardia and increased forward flow).
Q: Does the Austin Flint murmur have presystolic accentuation? A: It can, provided the patient is in normal sinus rhythm (atrial kick pushes the final volume past the leaflet).
Q: What echocardiographic finding correlates with this? A: Diastolic fluttering of the anterior mitral valve leaflet.
Q: If Austin Flint is present, what is the clinical implication? A: The AR is severe, and the patient requires surgical evaluation.

17. Indications for "Valve-in-Valve" TAVI.

Response Template: Physiological Principle: Surgical bioprosthetic valves (tissue valves) degenerate over 10-15 years via calcification and leaflet tearing (Structural Valve Deterioration - SVD). Guideline Application (ESC 2025): Re-do open heart surgery (sternotomy) carries high morbidity/mortality. "Valve-in-Valve" TAVI is indicated as a Class I or IIa option for patients with symptomatic failure of a surgical bioprosthesis who are deemed high or intermediate risk for redo surgery. A transcatheter valve is expanded directly inside the failing surgical valve frame, using it as an anchor.
Cross-Examination (5 Q&A):

Q: What is the most feared complication of aortic Valve-in-Valve TAVI? A: Coronary artery obstruction (the old surgical leaflets are pushed outward over the coronary ostia).
Q: What is the BASILICA procedure? A: Bioprosthetic or native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery obstruction; an electrocautery wire slices the old leaflet down the middle before TAVI deployment so blood can flow past it.
Q: What is Patient-Prosthesis Mismatch (PPM)? A: The inner diameter of the old surgical valve limits the size of the new TAVI valve, leaving the patient with high residual gradients (pseudo-stenosis).
Q: How can you prevent PPM during Valve-in-Valve? A: Bioprosthetic Valve Fracture (inflating a high-pressure balloon to intentionally fracture the old surgical ring to allow full TAVI expansion).
Q: Can Valve-in-Valve be done in the mitral position? A: Yes, Transcatheter Mitral Valve-in-Valve (via transseptal approach) is highly successful for failing surgical mitral rings or bioprostheses.

18. Why do we perform a TEE in suspected endocarditis?

Response Template: Physiological Principle: Ultrasound waves are attenuated by air (lungs) and bone (ribs). Transesophageal Echocardiography (TEE) places the probe in the esophagus, mere millimeters directly behind the Left Atrium, bypassing all acoustic interference. Pathophysiology/Guidelines: While Transthoracic Echo (TTE) is the first line, it lacks spatial resolution for small vegetations (<2-3 mm), posterior structures (Mitral Valve), prosthetic valves (metal artifact), and catastrophic complications (aortic root abscess, fistula, pseudoaneurysm). If clinical suspicion is high (e.g., Staph aureus bacteremia) and TTE is negative or non-diagnostic, Guidelines mandate an urgent TEE to confirm the diagnosis and plan surgery.
Cross-Examination (5 Q&A):

Q: If the initial TEE is negative, but suspicion remains high, what is the next step? A: Repeat the TEE in 5 to 7 days (vegetations may have been too small initially but grow rapidly).
Q: Which valve is hardest to see on TTE but perfectly visualized on TEE? A: The Mitral Valve (especially the atrial surface where vegetations attach).
Q: Is TTE sufficient for prosthetic valve endocarditis? A: Almost never. TEE is mandatory for suspected prosthetic valve endocarditis due to shadowing from the metallic ring.
Q: What defines an abscess on TEE? A: A thickened, echolucent (dark) area around the valve annulus, often extending into the septum.
Q: Is TEE a major or minor Duke criterion? A: Positive Echo findings (vegetation, abscess, new dehiscence) constitute a Major criterion.

19. Explain the mechanism of "Secondary" MR.

Response Template: Physiological Principle: Normal mitral valve competence requires precise balance between closing forces (LV contractility) and tethering forces (papillary muscles/chordae). Pathophysiology: In Secondary (Functional) MR, the valve leaflets are structurally normal. The pathology lies in the Left Ventricle. Due to ischemic or non-ischemic dilated cardiomyopathy, the LV dilates and becomes spherical. This displaces the papillary muscles laterally and apically, exerting massive tethering forces on the leaflets, pulling them down into the ventricle (apical tenting) and preventing coaptation. Annular dilation further widens the gap. Guideline Application: Treatment primarily targets the LV (GDMT, CRT). If the patient remains highly symptomatic despite maximal therapy, Transcatheter Edge-to-Edge Repair (MitraClip) is indicated based on the COAPT trial criteria.
Cross-Examination (5 Q&A):

Q: How do you differentiate primary from secondary MR on Echo? A: Primary MR has abnormal leaflets (prolapse, flail, thickened); Secondary MR has normal leaflets restricted by tethering (tenting).
Q: What is the "Tenting Area"? A: The space created between the annular plane and the restricted leaflets during systole; a larger area correlates with more severe MR.
Q: Why did the COAPT trial succeed when MITRA-FR failed? A: COAPT selected patients with "proportionate" MR (massive MR relative to the degree of LV dilation) who had exhausted all GDMT, whereas MITRA-FR included massively dilated burnt-out ventricles.
Q: Does aggressive diuresis improve Secondary MR? A: Yes, removing volume shrinks the LV cavity, reducing papillary tethering and improving coaptation.
Q: What is the surgical treatment if performing concurrent CABG? A: An undersized, rigid Mitral Annuloplasty ring to pull the posterior annulus forward and force coaptation.

20. How to calculate MVA using the Continuity Equation.

Response Template: Physiological Principle: The principle of Conservation of Mass dictates that in the absence of shunts or significant regurgitation, the volume of blood flowing through the Left Ventricular Outflow Tract (LVOT) must equal the volume flowing through the Mitral Valve. Calculation: Stroke Volume (SV) = Area x Velocity-Time Integral (VTI). Therefore, Area(LVOT) x VTI(LVOT) = Area(Mitral) x VTI(Mitral). Rearranged: Mitral Valve Area (MVA) = [Area(LVOT) x VTI(LVOT)] / VTI(Mitral). Guideline Application: This is a vital alternative method for calculating MVA when standard 2D planimetry is technically difficult (poor acoustic windows) and when the Pressure Half-Time (PHT) method is inaccurate (e.g., immediately post-PTMC, changing LV compliance, or severe Aortic Regurgitation).
Cross-Examination (5 Q&A):

Q: How do you calculate the LVOT Area? A: Measure the LVOT diameter in the Parasternal Long Axis view in mid-systole, then use the formula π x (radius)².
Q: Where is the greatest source of error in this equation? A: Measuring the LVOT diameter, because any small error is squared in the area formula.
Q: When is the Continuity Equation completely invalid for MS? A: If the patient has significant Mitral Regurgitation or Aortic Regurgitation, because the stroke volumes are no longer equal.
Q: Why is Pressure Half-Time (PHT) inaccurate post-PTMC? A: The sudden relief of stenosis acutely alters LA and LV compliance, rendering the PHT constant (220) invalid for 24-48 hours.
Q: How is the VTI of the mitral valve obtained? A: Using Continuous Wave (CW) Doppler across the mitral valve from the apical 4-chamber view, tracing the diastolic spectral envelope.

III. CORONARY ARTERY DISEASE & ACUTE MI (20 QUESTIONS)

1. Describe the "Plaque rupture vs. erosion" pathophysiology.

Response Template: Physiological Principle: Acute Coronary Syndrome (ACS) is driven by disruption of an atherosclerotic plaque, but the mechanisms differ. Pathophysiology: Plaque rupture involves a Thin-Cap Fibroatheroma (TCFA) with a large necrotic lipid core and dense macrophage infiltration. The cap tears, exposing highly thrombogenic tissue factor, leading to a massive red (fibrin-rich) occlusive thrombus (classic STEMI). Plaque erosion occurs over a thick fibrous cap with minimal lipid; the endothelium denudes, exposing hyaluronan and recruiting neutrophils/NETs, forming a platelet-rich white thrombus (often NSTEMI). Guideline Application: Both require immediate antithrombotic therapy and evaluation for invasive strategy, though erosions (often seen in younger females/smokers) have lower lipid burdens and slightly different long-term remodeling risks.
Cross-Examination (5 Q&A):

Q: Which imaging modality best differentiates rupture from erosion in vivo? A: Optical Coherence Tomography (OCT).
Q: What are the pathological features of a "vulnerable plaque"? A: Thin fibrous cap (<65 micrometers), large lipid core, spotty calcification, and active macrophage infiltration.
Q: Are most STEMIs caused by highly stenotic (>70%) or mildly stenotic plaques? A: Mildly stenotic plaques (often <50%), which are more numerous and have lipid-rich, unstable cores.
Q: What is a "calcified nodule"? A: A third, rarer cause of ACS where eruptive dense calcium fractures through the intima.
Q: Which type of thrombus is more resistant to fibrinolysis? A: Platelet-rich (white) thrombus seen in plaque erosion.

2. Why is Morphine used cautiously in ACS?

Response Template: Physiological Principle: Morphine is a potent opioid agonist providing analgesia and anxiolysis, which reduces sympathetic tone. Pathophysiology: Morphine severely delays gastric emptying and reduces intestinal motility. Guideline Application: This delayed gastric emptying significantly impairs the gastrointestinal absorption of oral P2Y12 inhibitors (Ticagrelor, Prasugrel, Clopidogrel). This leads to delayed platelet inhibition during the most critical early window of PCI, increasing the risk of acute stent thrombosis and recurrent ischemia. Guidelines now restrict morphine use only to severe, intractable pain unresponsive to nitrates.
Cross-Examination (5 Q&A):

Q: Does morphine directly reduce preload? A: Yes, it is a mild venodilator.
Q: What alternative strategy can be used if morphine is required? A: Crushed P2Y12 inhibitors or bridging with an IV agent like Cangrelor or a GP IIb/IIIa inhibitor.
Q: What is the CRUSADE registry finding regarding morphine? A: It was associated with higher mortality in NSTEMI patients, driving the guideline change.
Q: Can NSAIDs be used for pain in ACS? A: Absolute contraindication; they increase the risk of MACE and myocardial rupture.
Q: If a patient has severe anxiety and pain, what non-opioid is preferred? A: IV Nitroglycerin (if blood pressure allows) or short-acting benzodiazepines for anxiety.

3. Mechanism of DAPT (Aspirin vs. P2Y12 inhibitors).

Response Template: Physiological Principle: Platelet activation and aggregation rely on multiple redundant signaling pathways. Pathophysiology: Aspirin irreversibly inhibits COX-1, halting the production of Thromboxane A2 (TxA2), a potent platelet agonist and vasoconstrictor. P2Y12 inhibitors block the ADP receptor, preventing ADP-mediated sustained platelet activation and glycoprotein IIb/IIIa cross-linking. Guideline Application: Dual Antiplatelet Therapy (DAPT) provides synergistic blockade of both the TxA2 and ADP pathways. It is mandatory for 12 months following ACS to prevent stent thrombosis and recurrent atherothrombotic events.
Cross-Examination (5 Q&A):

Q: Which P2Y12 inhibitors are prodrugs requiring hepatic activation? A: Clopidogrel and Prasugrel (thienopyridines).
Q: Which P2Y12 inhibitor is direct-acting and reversible? A: Ticagrelor.
Q: Why is Prasugrel contraindicated in patients with a history of stroke/TIA? A: Unacceptably high risk of fatal intracranial hemorrhage (TRITON-TIMI 38 trial).
Q: What is the maintenance dose of Aspirin post-ACS? A: 75-100 mg daily (higher doses increase bleeding without adding ischemic benefit).
Q: How long does the antiplatelet effect of Aspirin last? A: The lifetime of the platelet (7-10 days), as platelets lack nuclei to synthesize new COX-1.

4. What is "Reperfusion Injury" and why does it happen?

Response Template: Physiological Principle: Myocardial salvage depends on restoring blood flow, but the sudden reintroduction of oxygen to ischemic tissue is inherently toxic. Pathophysiology: Reperfusion triggers a massive burst of Reactive Oxygen Species (ROS) and severe intracellular calcium overload. This causes the opening of the Mitochondrial Permeability Transition Pore (mPTP), leading to loss of ATP production, mitochondrial swelling, and cellular apoptosis. It also causes hypercontracture (contraction band necrosis). Guideline Application: Reperfusion injury can account for up to 50% of the final infarct size. While we cannot currently prevent it pharmacologically, achieving a rapid door-to-balloon time limits the baseline ischemic damage before reperfusion occurs.
Cross-Examination (5 Q&A):

Q: What ECG sign indicates successful reperfusion but also reperfusion injury? A: Accelerated Idioventricular Rhythm (AIVR).
Q: What is "Lethal Reperfusion Injury"? A: Death of cardiomyocytes that were viable at the very moment of reperfusion.
Q: What is ischemic preconditioning? A: Brief, repeated episodes of ischemia prior to the main infarct that paradoxically protect the myocardium and reduce infarct size.
Q: Does cyclosporine prevent reperfusion injury? A: It blocks the mPTP in animal models, but failed to show clinical benefit in large human trials (CIRCUS trial).
Q: What is remote ischemic conditioning? A: Inflating a BP cuff on an arm to induce transient ischemia, theoretically releasing humoral factors to protect the heart (mixed trial results).

5. Why do we avoid Beta-blockers in acute cardiogenic shock?

Response Template: Physiological Principle: Beta-blockers are negative inotropes (reduce contractility) and negative chronotropes (reduce heart rate). Pathophysiology: In acute cardiogenic shock (e.g., massive anterior STEMI), the Left Ventricle has failed. The patient's survival relies entirely on a massive compensatory surge of endogenous catecholamines driving the uninfarcted myocardium to maintain cardiac output. Guideline Application: Administering a beta-blocker in Killip Class III (pulmonary edema) or Class IV (shock) removes this critical compensatory drive, precipitating immediate hemodynamic collapse and death. Beta-blockers must be delayed until the patient is euvolemic and hemodynamically stable.
Cross-Examination (5 Q&A):

Q: What is the COMMIT trial finding? A: Early IV beta-blockers in acute MI reduce VF/re-infarction but significantly increase the risk of cardiogenic shock.
Q: When should oral beta-blockers be initiated post-MI? A: Within the first 24 hours, provided the patient is hemodynamically stable, has no signs of HF, and no heart block.
Q: Which beta-blockers are proven to reduce mortality in HFrEF post-MI? A: Carvedilol, Metoprolol Succinate, and Bisoprolol.
Q: What is the mechanism of beta-blocker benefit post-MI? A: Reduces myocardial oxygen demand, limits infarct size, and dramatically raises the ventricular fibrillation threshold (anti-arrhythmic).
Q: If a patient on chronic beta-blockers presents in shock, what is done? A: Withhold the beta-blocker immediately.

6. Pathophysiology of "No-reflow" phenomenon in PCI.

Response Template: Physiological Principle: Epicardial artery patency does not guarantee myocardial tissue perfusion. Pathophysiology: No-reflow occurs when microvascular beds are obliterated despite an open culprit artery. It is driven by four mechanisms: 1) Distal embolization of plaque/thrombus debris during stent deployment; 2) Ischemic endothelial swelling causing capillary occlusion; 3) Microvascular vasospasm; 4) In-situ microvascular thrombosis (MVO). Guideline Application: Presents as TIMI 0-1 flow, persistent ST elevation, and chest pain post-PCI. Treatment involves intracoronary vasodilators (Adenosine, Verapamil, Nitroprusside) and GP IIb/IIIa inhibitors to break the microvascular spasm and dissolve micro-thrombi.
Cross-Examination (5 Q&A):

Q: How does no-reflow affect prognosis? A: Extremely poor prognosis; massive increase in mortality, heart failure, and LV remodeling.
Q: What does it look like on Cardiac MRI? A: Microvascular Obstruction (MVO) – a dark, hypo-enhanced core within the bright infarct zone on LGE.
Q: Do aspiration thrombectomy catheters prevent no-reflow? A: Routine use is not recommended (TOTAL trial), as it does not improve mortality and increases stroke risk, but can be used as a bailout for massive thrombus burden.
Q: How do you assess tissue perfusion beyond TIMI flow? A: TIMI Myocardial Blush Grade (MBG) and resolution of ST-segment elevation.
Q: Which type of MI is most prone to no-reflow? A: Late-presenting anterior STEMI with high thrombus burden.

7. How to manage "In-stent restenosis" (ISR)?

Response Template: Physiological Principle: Stent struts cause deep arterial injury, prompting a healing response. Pathophysiology: Bare Metal Stents (BMS) fail via Neointimal Hyperplasia (aggressive smooth muscle cell proliferation). Drug-Eluting Stents (DES) fail much later, often via Neoatherosclerosis (new lipid-laden plaques forming inside the old stent). Guideline Application: First, use intravascular imaging (IVUS/OCT) to rule out mechanical causes (stent under-expansion or fracture). If true biological ISR is present, guidelines recommend treatment with a Drug-Coated Balloon (DCB) to avoid multiple layers of metal, or deploying a new, different generation DES inside the old one.
Cross-Examination (5 Q&A):

Q: Why is IVUS or OCT mandatory for treating ISR? A: If the original stent is simply under-expanded, placing a new stent won't help; you must dilate the old stent with a high-pressure non-compliant balloon.
Q: What anti-proliferative drugs are used on Drug-Coated Balloons? A: Paclitaxel or Sirolimus.
Q: What is the mechanism of Paclitaxel? A: Stabilizes microtubules, halting cell division at the G2/M phase.
Q: How does neoatherosclerosis differ from native atherosclerosis? A: It develops much faster (months to years instead of decades) due to incomplete endothelialization of the struts.
Q: What is brachytherapy? A: Intracoronary radiation used as a bailout for recurrent, refractory ISR to halt cell proliferation.

8. What is the "TIMI Flow Grade"?

Response Template: Physiological Principle: Angiographic assessment of epicardial coronary blood flow. Clinical Application: The TIMI (Thrombolysis in Myocardial Infarction) flow grade assesses the speed and completeness of contrast filling the distal bed.

TIMI 0: No flow past the obstruction.
TIMI 1: Faint penetration, but incomplete filling of the distal bed.
TIMI 2: Complete filling, but slower than normal clearance.
TIMI 3: Normal, brisk flow and clearance. Guideline Application: Achieving TIMI 3 flow is the primary angiographic endpoint of primary PCI. Anything less (TIMI 0-2) correlates with higher mortality and larger infarct size.

Cross-Examination (5 Q&A):

Q: Can a patient have TIMI 3 flow but still have a large infarct? A: Yes, if the door-to-balloon time was prolonged (the myocardium died before flow was restored) or if there is microvascular obstruction (no-reflow).
Q: What is the TIMI Myocardial Blush Grade (MBG)? A: It evaluates the actual tissue perfusion (capillary blushing) rather than just epicardial flow.
Q: What flow grade characterizes a classic STEMI before intervention? A: TIMI 0.
Q: What TIMI flow defines "no-reflow" post-stenting? A: TIMI 0 or 1 despite an open stent.
Q: Does thrombolysis achieve TIMI 3 flow as effectively as PCI? A: No, lytics only achieve TIMI 3 flow in about 50-60% of cases, compared to >90% with primary PCI.

9. Mechanism of ACE-inhibitors in post-MI remodeling.

Response Template: Physiological Principle: The Renin-Angiotensin-Aldosterone System (RAAS) is wildly activated post-MI to maintain blood pressure. Pathophysiology: While acutely beneficial, chronic Angiotensin II exposure is highly cardiotoxic. It stimulates fibroblast proliferation (collagen deposition/fibrosis) and myocyte hypertrophy in the uninfarcted tissue. This causes the LV to transition from an efficient elliptical shape to a dilated, inefficient spherical shape (Adverse Remodeling). Guideline Application: ACE inhibitors block the formation of Angiotensin II. They drop afterload, reduce wall stress, halt apoptosis, and prevent spherical remodeling. They are a Class 1 indication indefinitely post-MI, especially if LVEF <= 40% or anterior MI.
Cross-Examination (5 Q&A):

Q: When should an ACE inhibitor be started post-MI? A: Within the first 24 hours, once blood pressure is stable.
Q: Why is early initiation critical? A: Remodeling begins within hours of the infarct; early blockade prevents early cavity dilation.
Q: If a patient develops a severe cough on ACEi, what is the alternative? A: An Angiotensin Receptor Blocker (ARB) like Valsartan or Losartan.
Q: What causes the ACEi cough? A: Accumulation of bradykinin and substance P in the lungs (ACE normally degrades them).
Q: Do ACE inhibitors affect preload or afterload? A: Both (mixed vasodilators), though the afterload reduction is the primary hemodynamic benefit.

10. What is "Myocardial Stunning" vs "Hibernation"?

Response Template: Physiological Principle: The myocardium adapts to varying degrees and durations of ischemia to survive. Pathophysiology: Stunning follows an acute, severe ischemic insult (e.g., STEMI) that is rapidly reperfused. The tissue is viable and flow is normal, but contractile function takes days to weeks to recover due to transient calcium overload and ROS damage. Hibernation is an adaptation to chronic, severe hypoperfusion. The myocardium downregulates its metabolism and ceases contracting to match the low oxygen supply and avoid necrosis. Guideline Application: Hibernating myocardium is completely viable but akinetic. If identified by stress imaging (CMR, PET, Dobutamine Echo), CABG or PCI will fully restore its contractility, drastically improving EF.
Cross-Examination (5 Q&A):

Q: Does stunned myocardium respond to inotropes? A: Yes, it retains contractile reserve and will contract vigorously with dobutamine.
Q: What defines hibernation on a Cardiac PET scan? A: Mismatch pattern: Decreased perfusion (Ammonia/Rubidium) but preserved glucose metabolism (FDG uptake).
Q: What happens if you do not revascularize hibernating myocardium? A: It will eventually undergo apoptosis and transition into irreversible scar tissue.
Q: Is resting blood flow normal in stunning? A: Yes, reperfusion has occurred.
Q: Is resting blood flow normal in hibernation? A: No, it is chronically reduced.

11. ESC 2025 indications for CABG vs PCI in multivessel disease.

Response Template: Clinical Principle: Revascularization strategy must balance immediate procedural risk against long-term durability and survival. Guideline Application (ESC/ACC): The choice is driven by the Heart Team using the SYNTAX score and patient comorbidities. CABG is a Class I indication with a clear survival benefit over PCI in patients with: Multivessel disease AND Diabetes, severe Left Main disease with high SYNTAX (>32), or diffuse 3-vessel disease with reduced LVEF. PCI is preferred for low SYNTAX scores (<=22), single/double vessel disease without proximal LAD involvement, or patients with prohibitive surgical risk (frailty/severe COPD).
Cross-Examination (5 Q&A):

Q: Why does CABG provide a survival benefit in diabetes? A: Diabetics have diffuse, distal microvascular disease. A bypass graft (LIMA) bypasses the entire proximal segment, protecting against future proximal plaque ruptures, whereas stents only fix focal lesions.
Q: Which bypass conduit has the best long-term patency? A: The Left Internal Mammary Artery (LIMA) to the LAD (>90% patency at 10 years).
Q: What is the EXCEL trial? A: Compared PCI vs CABG in Left Main disease; showed PCI is an acceptable alternative in low/intermediate complexity LM disease.
Q: What is the FAME trial approach? A: Using Fractional Flow Reserve (FFR) to guide PCI; only stenting lesions with FFR <= 0.80 improves outcomes over angiography-guided PCI.
Q: What is the ISCHEMIA trial? A: Showed that in stable ischemic heart disease, routine early invasive therapy (PCI/CABG) did not reduce death or MI compared to optimal medical therapy alone.

12. Why is LDL cholesterol "the lower the better"?

Response Template: Physiological Principle: Low-Density Lipoprotein (LDL) is the primary driver of atherogenesis. It penetrates the endothelium, oxidizes, and drives the inflammatory cascade that builds the necrotic core. Pathophysiology: Massive genetic, epidemiological, and pharmacological trial data (Mendelian randomization, FOURIER, ODYSSEY) prove a log-linear relationship: every 1 mmol/L (39 mg/dL) reduction in LDL-C yields a ~22% reduction in Major Adverse Cardiovascular Events (MACE). Guideline Application: There is no known physiological "floor" where low LDL becomes harmful. ESC guidelines mandate aggressive lowering for extreme risk (post-ACS) to an LDL target of < 55 mg/dL AND a >50% reduction from baseline. If a second event occurs within 2 years, the target is < 40 mg/dL.
Cross-Examination (5 Q&A):

Q: Does extremely low LDL (< 20 mg/dL) cause hemorrhagic stroke or cognitive decline? A: Extensive trial data (PCSK9 trials) show no increase in cognitive impairment or hemorrhagic stroke at these ultra-low levels.
Q: What happens to the plaque at LDL levels < 70 mg/dL? A: Plaque progression halts. At levels < 55 mg/dL, IVUS shows actual plaque regression (shrinkage of the necrotic core).
Q: What is the primary pathway for LDL clearance? A: Hepatic LDL receptors.
Q: What is the mechanism of PCSK9 inhibitors? A: They block the PCSK9 protein from degrading LDL receptors, allowing massive recycling of receptors and extreme LDL clearance from the blood.
Q: If a patient on max tolerated statin is at LDL 65 mg/dL post-ACS, what is the next step? A: Add Ezetimibe (Class 1 indication).

13. Pathophysiology of coronary vasospasm (Prinzmetal).

Response Template: Physiological Principle: Vascular smooth muscle tone is balanced by endothelial vasodilators (NO) and vasoconstrictors (endothelin). Pathophysiology: In Prinzmetal (variant) angina, there is severe endothelial dysfunction and hyperreactivity of the smooth muscle (driven by the Rho-kinase pathway). This causes intense, focal, or diffuse spasm of an epicardial artery, leading to transient, complete transmural ischemia without actual plaque rupture or thrombosis. Guideline Application: Presents as rest angina (often early morning) with transient ST-segment elevation. Treatment relies on high-dose Calcium Channel Blockers (Diltiazem/Amlodipine) to paralyze smooth muscle, and long-acting Nitrates. Beta-blockers are contraindicated as they unmask alpha-mediated vasoconstriction.
Cross-Examination (5 Q&A):

Q: What recreational drug is a classic trigger? A: Cocaine (blocks norepinephrine reuptake, causing severe alpha-mediated spasm).
Q: How is it diagnosed definitively in the cath lab? A: Provocative testing with intracoronary Ergonovine or Acetylcholine (which paradoxically causes spasm in dysfunctional endothelium).
Q: Is the coronary artery completely normal? A: Often there is mild, non-obstructive atherosclerosis at the site of the spasm.
Q: What is the prognosis? A: Generally excellent with CCB therapy, though severe prolonged spasm can cause VF or MI.
Q: Why does acetylcholine cause spasm in these patients? A: Normally, ACh stimulates endothelial NO release (vasodilation). If the endothelium is damaged, ACh acts directly on the underlying smooth muscle muscarinic receptors, causing intense vasoconstriction.

14. Indications for MRA (Eplerenone/Spironolactone) post-MI.

Response Template: Physiological Principle: Aldosterone causes renal sodium retention, but in the heart, it is a potent stimulator of fibroblast activity and collagen deposition. Pathophysiology: Post-MI, Aldosterone escapes ACE inhibitor suppression ("Aldosterone breakthrough"). It directly drives myocardial fibrosis, electrical remodeling, and ventricular arrhythmias. Guideline Application: Based on the EPHESUS trial, Mineralocorticoid Receptor Antagonists (MRAs) are a Class 1 indication post-MI in patients with an LVEF <= 40% AND either symptomatic heart failure or Diabetes Mellitus. They significantly reduce sudden cardiac death and heart failure progression.
Cross-Examination (5 Q&A):

Q: What is the primary difference between Spironolactone and Eplerenone? A: Eplerenone is highly selective for the mineralocorticoid receptor; Spironolactone binds androgen and progesterone receptors, causing gynecomastia and menstrual irregularities.
Q: What are the two major contraindications to starting an MRA? A: Severe renal impairment (eGFR < 30) and baseline hyperkalemia (K+ > 5.0 mEq/L).
Q: Does adding an MRA to an ACEi increase hyperkalemia risk? A: Yes, dual RAAS blockade requires strict monitoring of potassium and creatinine at 1, 4, 8, and 12 weeks.
Q: Do MRAs provide afterload reduction in HF? A: Very minimally; their benefit is almost entirely anti-fibrotic and anti-arrhythmic at the low doses used in HF.
Q: Are MRAs indicated in HFpEF? A: Yes, (TOPCAT trial data), guidelines give them a Class IIa/IIb indication for reducing hospitalizations in HFpEF.

15. Describe the "SYNTAX score" utility.

Response Template: Clinical Principle: Not all multivessel disease is anatomically equal. Guideline Application: The SYNTAX score is a comprehensive angiographic grading tool that calculates the anatomical complexity of coronary artery disease. It accounts for the number of lesions, location, bifurcations, tortuosity, heavy calcification, and total occlusions.

Low Score (<= 22): PCI and CABG have similar mortality.
Intermediate (23-32): CABG is preferred, PCI is reasonable depending on comorbidities.
High Score (> 32): CABG provides a massive survival benefit; PCI is contraindicated unless surgery is prohibitive. The Heart Team uses this score to standardize revascularization decisions.

Cross-Examination (5 Q&A):

Q: Does the SYNTAX score include clinical variables (e.g., age, kidney function)? A: No, the classic SYNTAX score is purely anatomical.
Q: What is the SYNTAX II score? A: An updated version that integrates clinical variables (age, CrCl, LVEF, COPD, gender) with the anatomical score to individualize PCI vs CABG mortality prediction.
Q: Does the presence of a Chronic Total Occlusion (CTO) heavily increase the score? A: Yes, CTOs add significant complexity points.
Q: What lesion gets the highest weighting multiplier? A: Left Main coronary artery lesions.
Q: If a patient has a SYNTAX score of 35 but is 90 years old with severe COPD, what is done? A: PCI (or medical therapy), because the clinical surgical risk outweighs the anatomical benefit of CABG.

16. Why is high-dose Statin therapy mandatory post-ACS?

Response Template: Physiological Principle: HMG-CoA reductase inhibitors (Statins) lower LDL, but their rapid benefit in ACS is driven by lipid-independent "pleiotropic" effects. Pathophysiology: Statins rapidly improve endothelial function (increasing NO production), decrease oxidative stress, and profoundly reduce inflammation. They inhibit macrophage activity within the necrotic core and decrease matrix metalloproteinase (MMP) expression. Guideline Application: This rapidly thickens and stabilizes the thin fibrous cap of the ruptured (or vulnerable) plaque, preventing early recurrent ACS. High-intensity statin therapy (Atorvastatin 80mg or Rosuvastatin 40mg) must be initiated immediately upon admission for all ACS patients, regardless of baseline LDL levels.
Cross-Examination (5 Q&A):

Q: What is the PROVE-IT TIMI 22 trial? A: Proved that high-intensity statin (Atorvastatin 80mg) is superior to moderate-intensity (Pravastatin 40mg) in reducing MACE post-ACS.
Q: Does stopping a statin abruptly post-ACS carry risk? A: Yes, abrupt withdrawal causes a rebound inflammatory surge and severe endothelial dysfunction, increasing short-term mortality.
Q: What are the two high-intensity statins and their doses? A: Atorvastatin (40-80 mg) and Rosuvastatin (20-40 mg).
Q: What percentage LDL reduction defines "high-intensity"? A: A reduction of >= 50% from baseline.
Q: If transaminases (ALT/AST) rise to 2x upper limit of normal on high-dose statin, what is the action? A: Continue the statin and monitor; only stop or reduce if transaminases exceed 3x ULN.

17. Mechanism of Ticagrelor (Reversible vs Irreversible).

Response Template: Physiological Principle: Platelet ADP receptors (P2Y12) amplify platelet aggregation and stabilize the fibrin mesh. Pathophysiology: Clopidogrel and Prasugrel are prodrugs that permanently (irreversibly) covalently bind to the P2Y12 receptor. Platelet function is lost for the life of the platelet. Ticagrelor is a direct-acting agent that binds to an allosteric site on the P2Y12 receptor, causing a conformational change that prevents ADP from activating it. Guideline Application: Because Ticagrelor is direct-acting, it has a rapid onset (within 30 mins, crucial for primary PCI). Because it is reversible, its effects wear off as blood levels drop, allowing faster recovery of platelet function (offset) compared to Clopidogrel, making it safer if urgent CABG is required.
Cross-Examination (5 Q&A):

Q: What is the PLATO trial? A: Demonstrated Ticagrelor is superior to Clopidogrel in reducing CV death/MI in ACS patients, with no significant increase in fatal bleeding.
Q: Why does Ticagrelor cause dyspnea? A: It inhibits the equilibrative nucleoside transporter 1 (ENT1), raising extracellular adenosine levels, which stimulates pulmonary vagal C fibers.
Q: Does Ticagrelor dyspnea indicate worsening heart failure? A: No, it is usually benign and self-limiting.
Q: Can Ticagrelor cause bradycardia? A: Yes, also due to elevated adenosine levels affecting the AV/SA nodes.
Q: How many days should Ticagrelor be held before elective CABG? A: 3 to 5 days (compared to 5-7 days for Clopidogrel/Prasugrel).

18. What is the "Door-to-Balloon" time and why is it critical?

Response Template: Physiological Principle: In complete epicardial occlusion (STEMI), myocardial necrosis begins in the subendocardium and progresses outward toward the epicardium (the "Wavefront Phenomenon" of Reimer and Jennings). Pathophysiology: "Time is muscle." Transmural necrosis is generally complete within 6 to 12 hours. Reperfusion within the first 2-3 hours saves the vast majority of the epicardium, prevents pathological Q-wave formation, and halts negative remodeling. Guideline Application: ESC/ACC guidelines mandate a Door-to-Balloon time of < 90 minutes for patients presenting to a PCI-capable center, and < 120 minutes for patients requiring transfer. If transfer takes > 120 minutes, immediate thrombolysis (Door-to-Needle < 10 mins) is indicated.
Cross-Examination (5 Q&A):

Q: If a patient receives thrombolysis, what is the next step? A: Immediate transfer to a PCI center for a routine early invasive strategy (pharmaco-invasive approach) within 2-24 hours, or immediate rescue PCI if lytics fail.
Q: How do you know if thrombolysis failed? A: < 50% resolution of ST-segment elevation at 60-90 minutes, or persistent pain.
Q: What happens if reperfusion occurs after 12 hours? A: Little to no muscle is saved; the PCI is performed primarily to maintain an open artery for electrical stability (open artery hypothesis), though routine PCI of a totally occluded artery >24 hrs post-MI in stable patients is Class III (OAT trial).
Q: What is the First Medical Contact (FMC) to ECG goal? A: < 10 minutes.
Q: Can primary PCI be delayed to wait for cardiac biomarker results? A: Absolute contraindication; STEMI is an ECG and clinical diagnosis. Waiting for troponin wastes myocardium.

19. How does smoking promote coronary plaque progression?

Response Template: Physiological Principle: Healthy endothelium produces Nitric Oxide (NO) and prostacyclin, maintaining a vasodilatory, anti-thrombotic state. Pathophysiology: Cigarette smoke delivers massive free radicals and carbon monoxide. Oxidative stress completely depletes NO, causing severe endothelial dysfunction. It oxidizes LDL (making it easily consumed by macrophages to form foam cells). Furthermore, it massively upregulates Tissue Factor and increases platelet adhesiveness. Guideline Application: Smoking simultaneously accelerates plaque formation (atherogenesis) and creates an intensely pro-thrombotic environment prone to sudden rupture. Total smoking cessation is a Class 1 mandate; it halves the risk of recurrent MI within 1 to 2 years, equaling the efficacy of statins.
Cross-Examination (5 Q&A):

Q: How does smoking affect HDL cholesterol? A: It significantly lowers HDL, removing reverse cholesterol transport.
Q: Does switching to vaping eliminate cardiovascular risk? A: No, e-cigarettes still deliver nicotine (sympathetic surge/vasoconstriction) and generate oxidative stress/endothelial dysfunction.
Q: What happens to carboxyhemoglobin levels? A: They rise, shifting the oxygen-hemoglobin dissociation curve to the left, worsening myocardial hypoxia during ischemia.
Q: Are smokers more prone to plaque rupture or erosion? A: They have a very high incidence of plaque erosion causing acute thrombosis.
Q: Is varenicline (Chantix) safe in CAD patients? A: Yes, trials (EAGLES) have shown it is safe and highly effective for smoking cessation in cardiovascular patients.

20. Pathophysiology of "Stable vs. Unstable" angina.

Response Template: Physiological Principle: Angina is a manifestation of myocardial oxygen supply-demand mismatch. Pathophysiology: Stable angina is driven by a fixed, heavily calcified, thick-capped atherosclerotic plaque that obstructs >70% of the lumen. At rest, distal vasodilation provides enough supply. With exertion, demand rises, but the fixed stenosis prevents flow increase, causing predictable ischemia. Unstable angina is an Acute Coronary Syndrome. It is caused by the sudden rupture or erosion of an unstable (often non-obstructive) plaque, generating a dynamic, partially occlusive thrombus. Guideline Application: Stable angina is managed medically (Beta-blockers, CCBs, Nitrates) to reduce demand, with elective PCI for refractory symptoms (ISCHEMIA trial). Unstable angina indicates impending infarction and requires immediate antiplatelet/anticoagulant therapy and an early invasive strategy (angiography within 24 hours).
Cross-Examination (5 Q&A):

Q: What are the three clinical presentations that define Unstable Angina? A: Rest angina (>20 mins), new-onset severe angina, or crescendo angina (increasing frequency/duration/intensity).
Q: How do you differentiate Unstable Angina from NSTEMI? A: Cardiac biomarkers (Troponin). They are negative in UA and positive in NSTEMI.
Q: What limits coronary flow at rest in stable CAD? A: Usually nothing, until the stenosis exceeds 90% (critical stenosis).
Q: Does stenting a stable plaque prevent future MIs? A: No, the COURAGE and ISCHEMIA trials proved that stenting stable disease relieves symptoms but does not reduce the risk of future MI or death.
Q: Why does stenting stable disease not prevent MI? A: Because future MIs usually occur from the sudden rupture of mild, non-obstructive plaques elsewhere in the coronary tree, which are treated by medical therapy (statins/aspirin), not focal stents.

IV. ARRHYTHMIAS & ELECTROPHYSIOLOGY (20 QUESTIONS)

1. What is "Atrial Remodeling" in AF?

Response Template: Physiological Principle: Normal atrial myocytes maintain a stable resting membrane potential and contract synchronously. Pathophysiology: "AF begets AF." Rapid atrial rates cause intracellular calcium overload. To protect against cell death, myocytes downregulate calcium channels (Electrical Remodeling), which shortens the Effective Refractory Period (ERP), making it easier for AF to sustain. Over time, fibroblasts lay down collagen (Structural Remodeling), causing atrial dilation and isolating myocyte bundles, which creates a permanent substrate for multiple re-entry wavelets. Guideline Application: Due to remodeling, long-standing AF becomes irreversible. The EAST-AFNET 4 trial and recent guidelines strongly advocate for early rhythm control (ablation or antiarrhythmics) within the first year of diagnosis to halt this pathological progression and reduce CVD
Cross-Examination (5 Q&A):

Q: Which type of remodeling happens first? A: Electrical remodeling happens within hours to days; structural remodeling takes weeks to months.

Q: Can electrical remodeling be reversed? A: Yes, restoring SR can reverse electrical remodeling within a few weeks.

Q: Does structural remodeling reverse? A: Once significant fibrosis occurs, it is largely irreversible, leading to permanent AF.

Q: What initiates paroxysmal AF? A: Ectopic triggers, typically from sleeves of myocardium extending into the pulmonary veins.

Q: What maintains persistent AF? A: The fibrotic atrial substrate (the "rotors" and multiple re-entry wavelets).

2. Explain the "Re-entry" circuit mechanism (WPW).

Response Template: Physiological Principle: Normal conduction flows in one direction and extinguishes after ventricular depolarization. Pathophysiology: Re-entry requires three elements: two distinct parallel pathways connecting the same tissues, different conduction velocities, and different refractory periods. In Wolff-Parkinson-White (WPW), the AV node (slow conduction, short refractory) and the accessory pathway (fast conduction, long refractory) form the loop. A premature atrial beat arrives when the accessory pathway is refractory, travels down the slow AV node, and by the time it reaches the ventricle, the accessory pathway has recovered. The signal travels retrogradely up the accessory pathway, forming an endless loop (Orthodromic AVRT). Guideline Application: Radiofrequency catheter ablation of the accessory pathway is a Class I recommendation for symptomatic WPW, as it permanently severs one limb of the circuit.
Cross-Examination (5 Q&A):

Q: What is Antidromic AVRT? A: Conduction travels down the accessory pathway and up the AV node (produces a wide-complex tachycardia).

Q: Why is Orthodromic AVRT a narrow-complex tachycardia? A: Because anterograde conduction to the ventricles occurs via the normal His-Purkinje system.

Q: What initiates the re-entry circuit? A: Usually a Premature Atrial Contraction (PAC) or Premature Ventricular Contraction (PVC).

Q: Why is Atrial Fibrillation dangerous in WPW? A: The accessory pathway lacks the decremental (delaying) properties of the AV node; AF impulses conduct 1:1, precipitating Ventricular Fibrillation (VF).

Q: What drugs are strictly contraindicated in WPW with AFib? A: AV nodal blockers (Verapamil, Beta-blockers, Digoxin, Adenosine) because they force all conduction down the dangerous accessory pathway.

3. Why does AFib cause a "pulse deficit"?

Response Template: Physiological Principle: Generating a palpable peripheral pulse requires a sufficient stroke volume, which in turn requires adequate diastolic filling time. Pathophysiology: In Atrial Fibrillation, ventricular depolarization is irregularly irregular. Some RR intervals are so short that the ventricle has almost no time to fill in diastole. When the ventricle contracts, it generates just enough pressure to open the aortic valve, but the stroke volume is too tiny to propagate a pressure wave all the way to the radial artery. Guideline Application: Because of this "pulse deficit" (heart rate by auscultation > pulse rate by palpation), guidelines mandate using a 12-lead ECG or apical auscultation, not radial palpation, to accurately assess ventricular rate control in AFib.
Cross-Examination (5 Q&A):

Q: Does the "atrial kick" loss contribute to this? A: Yes, losing the 20-30% volume contribution of atrial contraction exacerbates the low stroke volume of early beats.

Q: Is pulse deficit unique to AFib? A: No, it can occur with frequent Premature Ventricular Contractions (PVCs).

Q: What happens to the blood pressure during these short RR interval beats? A: The systolic blood pressure for those specific beats drops significantly.

Q: What is the optimal resting heart rate target in permanent AFib (RACE II trial)? A: Lenient control (heart rate < 110 bpm) is non-inferior to strict control (< 80 bpm), provided the patient is asymptomatic.

Q: How does a pulse deficit affect automated BP cuffs? A: It causes frequent machine errors and inaccurate readings; manual sphygmomanometry is required.

4. Mechanism of Adenosine in SVT.

Response Template: Physiological Principle: Adenosine is an endogenous purine nucleoside acting on A1 receptors in the AV node and SA node. Pathophysiology: Binding to A1 receptors opens acetylcholine-sensitive potassium channels (IKAch). The massive efflux of potassium severely hyperpolarizes the AV nodal cells. Simultaneously, it decreases cAMP, inhibiting calcium influx. This causes a transient, complete block of AV nodal conduction. Guideline Application: It is the Class I drug of choice for the acute termination of hemodynamically stable, narrow-complex regular tachycardias (AVNRT/AVRT). It breaks the re-entry circuit by blocking the AV nodal limb.
Cross-Examination (5 Q&A):

Q: Why does it require a rapid IV push followed by a flush? A: It has a half-life of less than 10 seconds due to rapid cellular uptake and deamination by erythrocytes.
Q: Does Adenosine terminate Atrial Flutter or Atrial Fibrillation? A: No, because the AV node is not part of the flutter/fib circuit. It will only transiently slow the ventricular rate, unmasking the flutter waves diagnostically.
Q: What beverage blocks adenosine receptors? A: Caffeine and Theophylline (methylxanthines), requiring higher doses of adenosine to achieve effect.
Q: In what condition is Adenosine contraindicated? A: Severe reactive airway disease (Asthma) as it can cause profound bronchospasm via A2B/A3 receptors.
Q: What is a normal patient sensation during administration? A: Flushing, chest tightness, and a brief feeling of impending doom (due to transient asystole).

5. Describe "Torsades de Pointes" (triggered by what?).

Response Template: Physiological Principle: Ventricular repolarization depends on a delicate balance of outward potassium currents and inward sodium/calcium currents. Pathophysiology: When outward potassium currents are blocked (e.g., genetic mutation, drugs, hypokalemia), the action potential duration drastically lengthens (Prolonged QT interval). This allows L-type calcium channels to recover and reopen during Phase 2 or 3, causing Early After-Depolarizations (EADs). If an EAD reaches threshold, it triggers polymorphic VT that twists around the isoelectric line. Guideline Application: Treatment of Torsades (regardless of serum level) requires immediate IV Magnesium Sulfate, which acts as a calcium channel blocker to suppress EADs. Temporary overdrive pacing (pacing the heart at 100-120 bpm) is also used to shorten the QT interval and prevent pauses.
Cross-Examination (5 Q&A):

Q: What defines a prolonged QTc? A: > 450 ms in men, > 460 ms in women.
Q: Why does bradycardia worsen Torsades? A: Slower heart rates naturally prolong repolarization (the QT interval), providing more time for EADs to form.
Q: What phenomenon immediately precedes the onset of Torsades? A: A "short-long-short" RR interval sequence.
Q: Which electrolyte abnormalities commonly cause it? A: Hypokalemia, Hypomagnesemia, and Hypocalcemia.
Q: Name common drug classes that prolong the QT interval. A: Macrolides (Azithromycin), Fluoroquinolones, Anti-psychotics (Haloperidol), and Class III antiarrhythmics (Sotalol, Dofetilide).

6. Why is Amiodarone the "universal" antiarrhythmic?

Response Template: Physiological Principle: Vaughan Williams classification divides drugs by single-channel blockades (I=Na, II=Beta, III=K, IV=Ca). Pathophysiology: Amiodarone is structurally unique; it blocks all four pathways. It primarily acts as a Class III (potassium channel blocker) prolonging the action potential, but its concurrent sodium, calcium, and beta-blocking properties stabilize the membrane uniformly. This prevents the severe transmural dispersion of repolarization that plagues other Class III drugs, making it highly effective but remarkably devoid of pro-arrhythmic (Torsades) risk. Guideline Application: It is the drug of choice for VT/VF in structural heart disease and the preferred agent for rhythm control in AFib patients with HFrEF. However, its massive iodine content and lipophilicity lead to severe long-term multi-organ toxicity.
Cross-Examination (5 Q&A):

Q: What is the half-life of amiodarone? A: Extremely long (up to 50-60 days) due to massive sequestration in adipose tissue.
Q: What is the most lethal extracardiac side effect? A: Pulmonary fibrosis (interstitial pneumonitis).
Q: How does it affect the thyroid? A: It contains heavy iodine; can cause Amiodarone-Induced Thyrotoxicosis (Type 1 or 2) or Hypothyroidism.
Q: What is the classic ocular finding? A: Corneal microdeposits (present in >90% of patients on chronic therapy, usually benign).
Q: Does Amiodarone prolong the QT interval? A: Yes, significantly, but paradoxically it rarely causes Torsades de Pointes.

7. Mechanism of Radiofrequency Ablation.

Response Template: Physiological Principle: Cardiac arrhythmias often depend on distinct focal triggers (e.g., pulmonary veins) or narrow anatomical isthmuses (e.g., Cavotricuspid isthmus). Pathophysiology: An ablation catheter delivers unmodulated, high-frequency alternating current (typically 300-500 kHz). The current causes the water molecules in the myocardial tissue to oscillate rapidly, generating resistive heating. When tissue temperature exceeds 50°C, coagulative necrosis occurs, permanently destroying the arrhythmogenic tissue while preserving the overall cardiac structure. Guideline Application: Radiofrequency Ablation (RFA) is the Class I definitive treatment for typical Atrial Flutter, AVNRT, WPW, and is highly recommended (often first-line) for symptomatic Atrial Fibrillation (Pulmonary Vein Isolation).
Cross-Examination (5 Q&A):

Q: What happens if the tissue temperature exceeds 100°C? A: Blood boils, forming a steam pop that can rupture the myocardium (causing tamponade) and create char/thrombus on the catheter tip.
Q: How is overheating prevented? A: Irrigated-tip catheters constantly pump saline through the tip to cool the tissue interface.
Q: What is Cryoablation? A: An alternative utilizing liquid nitrous oxide to freeze the tissue (-40 to -70°C), causing necrosis by ice crystal formation.
Q: Which method is preferred for AVNRT near the AV node? A: Cryoablation is often preferred in pediatrics or near the AV node because if heart block occurs during freezing, rewarming reverses it (cryomapping).
Q: What is the anatomical target for typical Atrial Flutter? A: The Cavotricuspid Isthmus (CTI), located between the IVC and the tricuspid valve.

8. What are the Brugada criteria for VT vs SVT?

Response Template: Physiological Principle: Wide-complex tachycardia (WCT) is Ventricular Tachycardia (VT) until proven otherwise. Pathophysiology: If a WCT originates above the ventricles (SVT with aberrancy), it utilizes the His-Purkinje system, retaining some typical bundle-branch morphology. If it originates in the ventricular muscle (VT), cell-to-cell conduction is sluggish, creating bizarre, wide morphologies not typical of BBB. Guideline Application: The Brugada algorithm differentiates them sequentially: 1) Absence of an RS complex in all precordial leads confirms VT. 2) RS interval > 100 ms in any precordial lead confirms VT. 3) Presence of AV dissociation confirms VT. 4) Morphology criteria for VT in V1/V2 and V6 confirms VT. If none are met, it is SVT with aberrancy.
Cross-Examination (5 Q&A):

Q: Why is AV dissociation the gold standard hallmark of VT? A: It proves the ventricles are beating independently and faster than the atria, which is impossible in SVT.
Q: What is a "fusion beat"? A: A beat where a sinus impulse and a ventricular ectopic impulse simultaneously depolarize the ventricle, creating a hybrid QRS morphology (confirms VT).
Q: What is a "capture beat"? A: A normal, narrow sinus beat that slips through the AV node and completely captures the ventricle in the midst of a WCT (confirms VT).
Q: If all precordial leads are positive (positive concordance) or negative (negative concordance), what is the diagnosis? A: Ventricular Tachycardia.
Q: What is the rule regarding Verapamil in a wide-complex tachycardia? A: Never give it. If the WCT is actually VT, Verapamil will cause severe vasodilation and negative inotropy, precipitating cardiovascular collapse.

9. Explain "AV dissociation" in Ventricular Tachycardia.

Response Template: Physiological Principle: The SA node normally governs the heart due to having the fastest automaticity. Pathophysiology: In VT, an ectopic ventricular focus or re-entry circuit fires at a rate (e.g., 180 bpm) that exceeds the SA node's rate (e.g., 90 bpm). The fast ventricular impulses encounter the AV node from below and are usually blocked by the node's refractory period (retrograde block). Therefore, the SA node continues to pace the atria independently of the ventricles. Guideline Application: Finding P waves marching through the QRS complexes at a slower, independent rate on an ECG guarantees the diagnosis of VT.
Cross-Examination (5 Q&A):

Q: Are P waves easy to see during VT? A: No, they are usually buried inside the wide T waves and QRS complexes.
Q: What physical exam sign on the neck indicates AV dissociation? A: Cannon 'a' waves in the jugular venous pulse.
Q: What auscultatory finding indicates AV dissociation? A: Varying intensity of the first heart sound (S1), depending on whether the mitral valve is wide open or partially closed when systole begins.
Q: Can VT conduct retrogradely 1:1 to the atria? A: Yes, in about 30% of cases, which obliterates AV dissociation (but it is still VT).
Q: If the atrial rate is FASTER than the ventricular rate, what is it? A: Atrial flutter/fibrillation or SVT with block, NOT VT.

10. Why is anticoagulation needed in AF (CHA2DS2-VASc score)?

Response Template: Physiological Principle: Virchow's Triad postulates that thrombosis requires stasis, endothelial injury, or hypercoagulability. Pathophysiology: In AFib, the left atrium loses its mechanical "kick." Blood stagnates, particularly in the trabeculated pouch of the Left Atrial Appendage (LAA). This profound stasis activates the coagulation cascade, forming fibrin-rich red thrombi that can embolize to the cerebral circulation. Guideline Application: The CHA2DS2-VASc score stratifies this stroke risk (Congestive HF, HTN, Age >=75, Diabetes, Stroke/TIA history, Vascular disease, Age 65-74, Sex category female). A score >= 2 in men or >= 3 in women is a Class I indication for lifelong Non-Vitamin K Oral Anticoagulants (NOACs/DOACs) to prevent cardioembolic stroke.
Cross-Examination (5 Q&A):

Q: Do antiplatelets (Aspirin) work for AFib stroke prevention? A: No, stasis causes fibrin-rich (red) thrombi, requiring anticoagulants. Aspirin prevents platelet-rich (white) thrombi seen in arteries.
Q: Which patients MUST use Warfarin instead of a NOAC? A: Patients with moderate-to-severe Rheumatic Mitral Stenosis or a Mechanical Prosthetic Valve.
Q: What is the HAS-BLED score? A: Evaluates bleeding risk. A high score does not contraindicate anticoagulation but flags modifiable risks (e.g., lowering BP, stopping NSAIDs).
Q: Where do 90% of AFib thrombi form? A: The Left Atrial Appendage.
Q: If a patient has a high CHA2DS2-VASc but severe, recurrent GI bleeding, what is the alternative? A: Percutaneous Left Atrial Appendage occlusion (Watchman device).

11. What is "Pacing Capture" vs "Sensing"?

Response Template: Physiological Principle: A permanent pacemaker must interpret the heart's intrinsic activity and deliver appropriately timed energy. Pathophysiology: Sensing is the ability of the lead to "see" intrinsic myocardial depolarizations (measured in millivolts). If the device senses an intrinsic beat, it inhibits its output. Capture is the ability of the electrical pulse delivered by the lead to successfully depolarize the myocardium, generating a contraction (measured in Volts or milliAmperes). Guideline Application: During device interrogation, sensing thresholds must be programmed high enough to avoid T-wave oversensing, and the pacing output must be programmed to at least 2x the capture threshold to ensure a safe margin without draining the battery.
Cross-Examination (5 Q&A):

Q: What is "Failure to Capture"? A: A pacing spike is seen on the ECG, but it is not followed by a P wave or QRS complex.
Q: What causes Failure to Capture? A: Lead dislodgement, lead fracture, or increased myocardial threshold (ischemia, hyperkalemia).
Q: What is "Undersensing"? A: The pacemaker fails to see an intrinsic beat and fires inappropriately (pacing spikes fall on top of intrinsic QRS or T waves).
Q: What is "Oversensing"? A: The pacemaker sees electrical noise (muscle tremors, EMI) as a heartbeat and inappropriately inhibits pacing, causing pauses.
Q: What is a hysteresis algorithm? A: Allows the intrinsic heart rate to drop slightly below the programmed pacing rate to encourage native conduction before the pacemaker kicks in.

12. How do pacemakers function in "Rate Response" mode?

Response Template: Physiological Principle: The healthy SA node responds to catecholamines and vagal withdrawal to increase heart rate during exertion. Pathophysiology: In Chronotropic Incompetence (severe SA node disease), the heart rate fails to increase appropriately with exercise, causing severe exertional dyspnea and fatigue. Guideline Application: Modern pacemakers are programmed in "Rate Response" mode (the 'R' in DDDR or VVIR). They utilize internal sensors (accelerometers to detect body motion, and minute-ventilation sensors measuring transthoracic impedance) to calculate the body's metabolic demand and artificially drive the pacing rate up during exertion.
Cross-Examination (5 Q&A):

Q: What does the first letter of the NBG code indicate? A: The chamber being paced (A = Atrium, V = Ventricle, D = Dual).
Q: What does the second letter indicate? A: The chamber being sensed.
Q: What does the third letter indicate? A: The response to sensing (I = Inhibited, T = Triggered, D = Dual).
Q: What happens if a patient with an accelerometer-only sensor rides a bicycle? A: Because the upper body is still, the pacemaker may fail to increase the heart rate.
Q: How is chronotropic incompetence formally defined? A: Failure to reach 85% of age-predicted maximum heart rate during maximal exercise testing.

13. Indications for ICD in non-ischemic cardiomyopathy.

Response Template: Physiological Principle: Both ischemic scar and non-ischemic fibrosis provide the substrate for lethal re-entry circuits. Pathophysiology: In Non-Ischemic Dilated Cardiomyopathy (NIDCM), diffuse mid-wall fibrosis causes electrical heterogeneity, predisposing to Ventricular Tachycardia and VF. Guideline Application: Primary prevention Implantable Cardioverter-Defibrillator (ICD) is a Class IIa recommendation for NIDCM patients with an EF <= 35%, NYHA Class II-III symptoms, and > 3 months of optimal GDMT. (It is a Class I recommendation for Ischemic cardiomyopathy). The downgrade to IIa for non-ischemic followed the DANISH trial, which showed less profound sudden death benefit in older NIDCM patients without scar on MRI.
Cross-Examination (5 Q&A):

Q: What Cardiac MRI finding strongly supports putting an ICD in an NIDCM patient? A: Presence of extensive mid-wall Late Gadolinium Enhancement (scar).
Q: Why wait 3 months after starting medical therapy before placing the ICD? A: GDMT (Beta-blockers, ARNI, MRA) facilitates reverse remodeling; the EF may recover above 35%, eliminating the need for the device.
Q: Can you place an ICD immediately post-myocardial infarction? A: No, you must wait 40 days post-MI (or 90 days post-revascularization) to allow for stunning recovery (DINAMIT/IRIS trials).
Q: What is Secondary Prevention? A: Placing an ICD in a patient who has already survived a cardiac arrest or documented hemodynamically unstable VT (Class I).
Q: What device is used to protect patients during the 40 or 90-day waiting period? A: A Wearable Cardioverter-Defibrillator (LifeVest).

14. Why avoid class 1C drugs in post-MI patients (CAST trial)?

Response Template: Physiological Principle: Class 1C antiarrhythmics (Flecainide, Propafenone) are potent sodium channel blockers that drastically slow Phase 0 of the action potential. Pathophysiology: In a post-MI patient, the scarred myocardium already conducts impulses very slowly. Adding a Class 1C drug slows conduction further. Instead of extinguishing an arrhythmia, this severe conduction slowing creates the perfect conditions for a deadly re-entry loop (the impulse travels so slowly that the original tissue has time to repolarize and be restimulated). Guideline Application: The landmark CAST (Cardiac Arrhythmia Suppression Trial) was halted early because post-MI patients treated with Class 1C drugs to suppress PVCs had a massively increased risk of sudden cardiac death. Class 1C drugs are absolutely contraindicated in patients with structural heart disease (CAD, prior MI, HF, severe LVH).
Cross-Examination (5 Q&A):

Q: In what patients are Class 1C drugs safe and indicated? A: Patients with structurally normal hearts (e.g., young patients with lone Atrial Fibrillation).
Q: What is "use dependence"? A: Class 1C drugs block sodium channels more effectively at higher heart rates.
Q: What happens to the QRS complex during exercise in a patient on Flecainide? A: It widens significantly due to use-dependence (can mimic VT).
Q: What is the "Pill-in-the-Pocket" approach? A: Giving a single high dose of Flecainide/Propafenone to a patient at home to terminate acute paroxysmal AFib (after ensuring their heart is structurally normal).
Q: What medication MUST be co-administered with Pill-in-the-Pocket Flecainide? A: An AV nodal blocker (Beta-blocker or CCB) to prevent 1:1 conduction of atrial flutter.

15. Pathophysiology of "Brugada Syndrome" (Sodium channel mutation).

Response Template: Physiological Principle: The cardiac action potential relies on a balance between depolarizing inward currents (Sodium) and repolarizing outward currents (Potassium). Pathophysiology: Brugada Syndrome involves a loss-of-function mutation in the SCN5A sodium channel. This decreases the inward sodium current, specifically in the epicardium of the Right Ventricular Outflow Tract (RVOT), where the transient outward potassium current (Ito) is highly active. This creates a severe transmural voltage gradient during Phase 1, causing epicardial repolarization to finish before the endocardium. This dispersion of repolarization triggers "Phase 2 re-entry," sparking polymorphic VT and VF. Guideline Application: Diagnosed by a Type 1 "coved" ST-segment elevation > 2mm in leads V1-V2. An ICD is the only proven therapy for symptomatic patients (syncope or survived SCA).
Cross-Examination (5 Q&A):

Q: When do Brugada patients typically arrest? A: During sleep or rest (when vagal tone is highest).
Q: What physiological state exacerbates the ECG pattern and increases arrest risk? A: Fever (increases inactivation of the mutant sodium channels).
Q: Which drug can unmask the Brugada ECG pattern? A: Sodium channel blockers (Ajmaline, Flecainide, Procainamide).
Q: Is Amiodarone effective for Brugada? A: No, antiarrhythmics do not prevent VF in Brugada syndrome; Quinidine (blocks Ito) is the only drug with some efficacy for storm.
Q: What does a Type 2 pattern look like? A: "Saddle-back" ST elevation (not diagnostic without provocation to Type 1).

16. What is the "Delta wave" in WPW?

Response Template: Physiological Principle: Normal AV node conduction is intentionally slow (to allow ventricular filling), generating the isoelectric PR segment. Pathophysiology: In Wolff-Parkinson-White, an aberrant band of myocardium (Bundle of Kent) connects the atria directly to the ventricles, bypassing the AV node. This accessory pathway has no conduction delay. The atrial impulse rushes down the pathway and begins depolarizing the ventricular myocardium cell-by-cell (which is slow) before the main impulse makes it through the AV node. Guideline Application: This pre-excitation creates a shortened PR interval (<120 ms) and a slurred, sluggish upstroke on the QRS complex—the Delta wave. Once the AV node impulse arrives and fires down the rapid His-Purkinje system, the rest of the QRS finishes normally (making the total QRS wide).
Cross-Examination (5 Q&A):

Q: What happens to the ST segment and T wave in WPW? A: Secondary repolarization abnormalities (T waves are opposite in direction to the Delta wave).
Q: Can WPW mimic a myocardial infarction? A: Yes, a negative Delta wave in the inferior leads looks like a pathological Q wave (pseudo-infarct).
Q: What defines "concealed" WPW? A: An accessory pathway that only conducts retrogradely (ventricle to atrium). It causes SVT but shows NO Delta wave on the resting ECG.
Q: Why is risk stratification testing performed? A: To see if the pathway loses conduction at high heart rates (via exercise test); if it blocks abruptly, the pathway has a long refractory period and is benign.
Q: If a patient has a Delta wave but has never had an arrhythmia, what is the diagnosis? A: WPW Pattern (not WPW Syndrome).

17. How does Carotid Massage terminate SVT?

Response Template: Physiological Principle: Baroreceptors in the carotid sinus monitor systemic blood pressure and relay signals via the glossopharyngeal nerve (CN IX) to the vagus nerve (CN X). Pathophysiology: Massaging the carotid sinus simulates high blood pressure. The vagus nerve reflexively dumps massive amounts of Acetylcholine (ACh) onto the SA and AV nodes. ACh activates muscarinic (M2) receptors, which open potassium channels and inhibit calcium channels, severely slowing AV nodal conduction. Guideline Application: In AVNRT or AVRT, the re-entry circuit obligatorily uses the AV node. Vagal maneuvers (Carotid massage, Valsalva) induce a transient AV block that severs the circuit, terminating the SVT. It is a Class I first-line maneuver for stable regular SVT.
Cross-Examination (5 Q&A):

Q: What is a strict contraindication to carotid massage? A: Presence of carotid bruits, history of TIA/Stroke, or advanced age (risk of dislodging an atherosclerotic plaque).
Q: How long should you massage? A: Firm pressure on one side for 5-10 seconds. NEVER massage both sides simultaneously.
Q: What is the "Modified Valsalva maneuver" (REVERT trial)? A: Patient blows into a syringe (40 mmHg pressure) for 15 seconds, followed immediately by supine positioning with passive leg raise (increases efficacy from 17% to 43%).
Q: Does vagal massage terminate Ventricular Tachycardia? A: No, the ventricles have very little vagal innervation.
Q: If vagal maneuvers fail, what is the next step? A: IV Adenosine.

18. Management of "Ventricular Storm."

Response Template: Physiological Principle: Ischemia or scar-induced arrhythmias trigger profound anxiety and pain, driving a massive sympathetic (catecholamine) surge, which further lowers the VF threshold, creating a lethal positive feedback loop. Pathophysiology: Electrical Storm is defined as >= 3 distinct episodes of VT/VF requiring termination within 24 hours. The beta-adrenergic surge constantly re-ignites the re-entry circuits around the scar. Guideline Application: Management requires breaking the sympathetic loop. Deep sedation/intubation is critical. Non-selective beta-blockers (IV Propranolol) are superior to cardioselective ones because they block all CNS/cardiac catecholamine activity. IV Amiodarone is the antiarrhythmic of choice. If refractory, emergent Radiofrequency Ablation of the VT substrate or Stellgate Ganglion block is indicated.
Cross-Examination (5 Q&A):

Q: Why is Amiodarone preferred over Lidocaine? A: Amiodarone acts globally on multiple channels and suppresses the sympathetic tone, whereas Lidocaine only works on ischemic sodium channels.
Q: What happens to the ICD during a storm? A: It continuously shocks the patient, traumatizing the myocardium, worsening the sympathetic surge, and draining the battery.
Q: Can you turn off the ICD therapies? A: Yes, via magnet application, provided the patient is connected to an external defibrillator and deeply sedated.
Q: What is the role of intra-aortic balloon pump (IABP) or ECMO? A: Hemodynamic unloading reduces myocardial oxygen demand and wall stress, stabilizing the electrical substrate.
Q: Why is Propranolol better than Metoprolol in this specific scenario? A: Propranolol is lipophilic (crosses the blood-brain barrier to sedate the CNS) and blocks presynaptic beta-2 receptors, severely blunting the catecholamine surge.

19. What is "His-bundle pacing"?

Response Template: Physiological Principle: The native His-Purkinje system is a high-speed electrical highway designed to depolarize the right and left ventricles simultaneously. Pathophysiology: Traditional Right Ventricular (RV) apical pacing creates an artificial Left Bundle Branch Block (LBBB). The slow, cell-to-cell spread of electricity from the RV to the LV causes dyssynchrony, which over years causes Pacing-Induced Cardiomyopathy (PICM). Guideline Application: Conduction System Pacing (His-bundle pacing or Left Bundle Branch Area pacing) involves screwing the pacing lead directly into the native His bundle. This engages the native highway, producing a perfectly narrow, physiological QRS. It prevents dyssynchrony and is becoming a frontline alternative to traditional biventricular CRT.
Cross-Examination (5 Q&A):

Q: What is the main technical challenge of His-bundle pacing? A: The target is very small, requiring specialized mapping, and capture thresholds are historically higher (draining the battery faster).
Q: What is Left Bundle Branch Area Pacing (LBBAP)? A: Screwing the lead deep through the interventricular septum to capture the left bundle branch directly; easier to hit and better thresholds than His pacing.
Q: If a patient has a complete AV block at the level of the AV node, will His pacing work? A: Yes, because the His bundle is distal to the AV node.
Q: If a patient has an infra-Hisian block (distal Purkinje disease), will His pacing work? A: Often no, because the block is below where the lead is pacing.
Q: What percentage of RV pacing burden justifies considering conduction system pacing? A: Anticipated pacing burden > 20-40%.

20. Why is AFib associated with TIA/Stroke?

Response Template: Physiological Principle: Virchow's Triad determines the risk of thrombosis: endothelial injury, hypercoagulability, and stasis. Pathophysiology: In Atrial Fibrillation, the atria quiver at 300-600 bpm rather than contracting. This results in complete loss of organized atrial emptying. Blood stagnates profoundly, specifically within the Left Atrial Appendage (LAA), a blind-ended, heavily trabeculated sac. This stasis activates coagulation factors, forming a massive red (fibrin) thrombus. Guideline Application: If the rhythm converts to sinus or if pieces of the friable clot break off, they travel out of the LA, into the LV, and directly up the carotid arteries (most commonly the Middle Cerebral Artery), causing catastrophic, large-territory cardioembolic strokes. Oral anticoagulation is mandatory based on the CHA2DS2-VASc score.
Cross-Examination (5 Q&A):

Q: How do cardioembolic strokes differ clinically from atherosclerotic strokes? A: Cardioembolic strokes are usually larger, more sudden in onset (maximal deficit at start), and have a higher risk of hemorrhagic conversion.
Q: What confirms the presence of LAA thrombus? A: Transesophageal Echocardiography (TEE).
Q: If a thrombus is found, can you perform a cardioversion? A: Absolute contraindication. Cardioversion will contract the atrium and eject the clot.
Q: How is the patient managed if a clot is found? A: 3-4 weeks of strict therapeutic anticoagulation, followed by a repeat TEE to confirm clot resolution before cardioversion.
Q: What is "Spontaneous Echo Contrast" (Smoke) on TEE? A: Swirling, echogenic blood flow indicating severe stasis and rouleaux formation of red blood cells, a precursor to frank thrombosis.

V. SYSTEMIC & CONGENITAL HEART DISEASE (20 QUESTIONS)

1. Why does ASD cause a "Fixed Split S2"?

Response Template: Physiological Principle: The second heart sound (S2) normally splits during inspiration because negative intrathoracic pressure increases venous return to the Right Ventricle, delaying pulmonic valve closure (P2). Pathophysiology: In an Atrial Septal Defect (ASD), the atria function as a common reservoir. During inspiration, systemic venous return increases, but the Left-to-Right shunt decreases. During expiration, systemic return decreases, but the Left-to-Right shunt increases. Thus, the RV receives a massive, constant volume of blood regardless of the respiratory cycle. Guideline Application: This constant RV volume overload permanently delays P2, causing a wide and "fixed" split S2. Identification of this sign warrants an echocardiogram; device closure is a Class I indication if there is evidence of RV volume overload (Qp:Qs > 1.5).
Cross-Examination (5 Q&A):

Q: Which type of ASD is most common? A: Ostium Secundum (75% of cases).
Q: What ECG finding is classic for an Ostium Primum ASD? A: Left Axis Deviation (superior axis) due to associated endocardial cushion defects.
Q: What ECG finding is classic for an Ostium Secundum ASD? A: Right Axis Deviation with incomplete RBBB.
Q: Can you close a Sinus Venosus ASD with a percutaneous device? A: No, it requires surgical patching due to proximity to the SVC and associated anomalous pulmonary veins.
Q: Why does a large ASD present with a mid-diastolic rumble? A: Relative tricuspid stenosis (massive volume flowing across a normal-sized tricuspid valve).

2. Pathophysiology of "Eisenmenger Syndrome."

Response Template: Physiological Principle: The pulmonary vasculature is designed for high volume, low resistance flow. Pathophysiology: A chronic, large, uncorrected Left-to-Right shunt subjects the pulmonary endothelium to years of massive shear stress. This triggers endothelial dysfunction, intimal hyperplasia, and medial hypertrophy (plexiform lesions). The pulmonary vascular resistance (PVR) progressively rises until it exceeds systemic vascular resistance (SVR). At this point, the shunt reverses (Right-to-Left). Guideline Application: The patient becomes cyanotic. Defect closure is now absolutely contraindicated (Class III), as the defect acts as a necessary "pop-off" valve for the failing RV. Treatment relies on advanced pulmonary vasodilators and palliative care/transplantation.
Cross-Examination (5 Q&A):

Q: Which defect causes Eisenmenger Syndrome the fastest? A: Truncus Arteriosus or a large VSD (exposes the lungs to systemic pressures immediately).
Q: Why is phlebotomy generally avoided despite severe erythrocytosis? A: It causes iron deficiency, rendering red blood cells rigid (microcytic) which increases hyperviscosity symptoms and stroke risk.
Q: What happens to the murmur when Eisenmenger develops? A: The original shunt murmur disappears because the pressures equalize across the defect.
Q: What is the classic clinical sign of Eisenmenger from a PDA? A: Differential cyanosis (pink upper body, cyanotic/clubbed lower body).
Q: What is the target oxygen saturation? A: Usually > 90%, but oxygen therapy has limited efficacy since the blood physically bypasses the lungs.

3. Why do we measure O2 saturations in CHD?

Response Template: Physiological Principle: Oxygen saturation should be uniform throughout the right heart (mixed venous) and left heart (systemic arterial). Pathophysiology: An abrupt increase in oxygen saturation (a "step-up") on the right side of the heart proves the admixture of oxygenated blood, pinpointing the anatomic level of a Left-to-Right shunt. A "step-down" on the left side indicates a Right-to-Left shunt. Guideline Application: During right heart catheterization, calculating the exact saturations in the SVC, IVC, RA, RV, and PA allows the use of the Fick Principle to calculate the Qp:Qs (Pulmonary flow to Systemic flow ratio). A Qp:Qs > 1.5 defines a hemodynamically significant shunt requiring intervention.
Cross-Examination (5 Q&A):

Q: What constitutes a significant O2 step-up at the atrial level (ASD)? A: An increase of >= 7% from the SVC/IVC to the Right Atrium.
Q: What constitutes a significant step-up at the ventricular level (VSD)? A: An increase of >= 5% from the RA to the Right Ventricle.
Q: How is mixed venous oxygen saturation (MvO2) calculated if there is an ASD? A: Flamm's equation: (3 x SVC saturation + 1 x IVC saturation) / 4.
Q: Why is IVC blood usually more saturated than SVC blood? A: The kidneys extract less oxygen than the brain.
Q: If the systemic saturation is 85% and the PA saturation is 60%, what is the likely diagnosis? A: A Right-to-Left shunt (e.g., Tetralogy of Fallot).

4. Mechanism of Sildenafil in PAH.

Response Template: Physiological Principle: Nitric Oxide (NO) stimulates soluble guanylate cyclase to produce cyclic GMP (cGMP), causing vascular smooth muscle relaxation. Phosphodiesterase type 5 (PDE5) degrades cGMP. Pathophysiology: In Pulmonary Arterial Hypertension (PAH), there is an imbalance favoring vasoconstrictors over vasodilators. Guideline Application: Sildenafil is a potent, selective PDE5 inhibitor. By preventing the breakdown of cGMP, it forces prolonged pulmonary vasodilation and inhibits smooth muscle proliferation. It is a Class I recommendation for Group 1 PAH, often used in upfront combination therapy with endothelin receptor antagonists. It is strictly contraindicated in patients taking nitrate medications due to profound, refractory hypotension.
Cross-Examination (5 Q&A):

Q: What is Tadalafil? A: A long-acting PDE5 inhibitor (dosed once daily compared to Sildenafil's three times daily).
Q: What is Riociguat? A: A soluble guanylate cyclase (sGC) stimulator; it directly creates cGMP independent of NO.
Q: Can you combine Sildenafil and Riociguat? A: Absolute contraindication (causes severe hypotension).
Q: What visual side effect is unique to Sildenafil? A: "Blue vision" (cyanopsia) due to mild cross-reactivity with PDE6 in the retina.
Q: Is Sildenafil indicated in Group 2 (Left Heart Disease) Pulmonary Hypertension? A: No, pulmonary vasodilators are generally avoided in Group 2 as they can precipitate acute pulmonary edema by overwhelming the stiff left heart.

5. Pathophysiology of "Coarctation" hypertension.

Response Template: Physiological Principle: Blood pressure is tightly regulated by the kidneys via the Renin-Angiotensin-Aldosterone System (RAAS) and by aortic arch baroreceptors. Pathophysiology: A mechanical narrowing at the aortic isthmus creates two zones: high pressure proximal to the stenosis (upper body) and low pressure distal (lower body). The hypoperfused kidneys sense low pressure and chronically hyper-secrete renin, driving systemic Angiotensin II and Aldosterone levels up. Simultaneously, the proximal baroreceptors "reset" to accept the high pressure as the new normal. Guideline Application: This causes severe, treatment-resistant upper extremity hypertension. Balloon angioplasty, stenting, or surgical repair is indicated for a peak-to-peak transcatheter gradient > 20 mmHg.
Cross-Examination (5 Q&A):

Q: What is the classic pulse discrepancy? A: Radio-femoral delay (femoral pulse occurs later and weaker than the radial pulse).
Q: What collateral arteries enlarge to bypass the block? A: Internal mammary arteries and intercostal arteries.
Q: What X-ray sign is produced by these collaterals? A: Inferior rib notching (usually ribs 3-8; ribs 1 and 2 are spared because their arteries arise from the costocervical trunk proximal to the coarctation).
Q: What congenital valve defect is present in up to 80% of coarctation patients? A: Bicuspid Aortic Valve (BAV).
Q: Does fixing the coarctation immediately cure the hypertension? A: Not always; long-standing neurohormonal remodeling often requires lifelong antihypertensive therapy even after successful relief of the obstruction.

6. Why is PDA associated with "Bounding pulses"?

Response Template: Physiological Principle: Pulse pressure is the difference between systolic and diastolic blood pressure. A normal pulse pressure is ~40 mmHg. Pathophysiology: In a Patent Ductus Arteriosus (PDA), there is a continuous communication between the descending aorta and the pulmonary artery. During systole, the LV ejects an enormous stroke volume (normal systemic requirements + the shunted volume), creating a very high systolic blood pressure. During diastole, blood rapidly runs off from the high-pressure aorta into the low-pressure pulmonary artery, causing the diastolic blood pressure to plummet. Guideline Application: This creates a massively wide pulse pressure (e.g., 140/40), felt clinically as "bounding" or water-hammer pulses. Device closure is indicated to prevent LV volume overload and heart failure.
Cross-Examination (5 Q&A):

Q: What is the classic murmur of a PDA? A: Continuous "machinery" murmur heard best at the left infraclavicular area.
Q: When is the murmur loudest? A: At the time of the second heart sound (S2), peaking as systole ends and diastole begins.
Q: How is a PDA kept open in a neonate with ductal-dependent CHD? A: Continuous infusion of Prostaglandin E1 (Alprostadil).
Q: How is a PDA pharmacologically closed in a premature infant? A: Cyclooxygenase inhibitors (Indomethacin or Ibuprofen).
Q: What infectious complication are PDA patients uniquely at high risk for? A: Endarteritis (vegetations form on the pulmonary artery side where the high-velocity jet strikes the endothelium).

7. Mechanism of "Ambrisentan" (Endothelin receptor antagonist).

Response Template: Physiological Principle: Endothelin-1 (ET-1) is the most potent endogenous vasoconstrictor, acting via ET-A receptors (vasoconstriction/proliferation) and ET-B receptors (vasodilation/clearance of ET-1). Pathophysiology: In PAH, endothelial dysfunction leads to massive overexpression of ET-1, driving severe pulmonary vasoconstriction and vascular remodeling. Guideline Application: Ambrisentan is a highly selective ET-A receptor antagonist. It blocks the harmful vasoconstrictive receptors while preserving the beneficial ET-B receptors that clear ET-1 and produce NO. Based on the AMBITION trial, upfront combination therapy with Ambrisentan and Tadalafil is a Class I recommendation for newly diagnosed PAH to drastically reduce clinical failure.
Cross-Examination (5 Q&A):

Q: How does Bosentan differ from Ambrisentan? A: Bosentan is a non-selective, dual ET-A and ET-B receptor antagonist.
Q: What is the major toxicity of Bosentan? A: Hepatotoxicity (requires monthly LFT monitoring). Ambrisentan has a much lower risk of liver injury.
Q: What is a common side effect of Ambrisentan? A: Peripheral edema (due to vasodilation).
Q: Are ERAs safe in pregnancy? A: No, all ERAs (Ambrisentan, Bosentan, Macitentan) are absolutely contraindicated (highly teratogenic).
Q: Can you use ERAs in Group 3 PAH (Lung disease)? A: No, they may worsen V/Q mismatch by reversing hypoxic pulmonary vasoconstriction.

8. Pathophysiology of "Takayasu Arteritis."

Response Template: Physiological Principle: The aorta and its primary branches supply the vital organs and extremities. Pathophysiology: Takayasu arteritis is a cell-mediated (T-cell) granulomatous inflammation of the aorta (large-vessel vasculitis). The chronic inflammation destroys the media and drives massive intimal hyperplasia and adventitial fibrosis. This causes long, smooth, circumferential stenoses or total occlusions of the aortic branches, or less commonly, aneurysms. Guideline Application: Often presenting in young females as "pulseless disease" with claudication. Active inflammation is treated with high-dose corticosteroids and immunosuppressants (Methotrexate/Tocilizumab). Surgical bypass or stenting is strictly reserved for the inactive/quiescent phase, as operating during active inflammation guarantees graft failure.
Cross-Examination (5 Q&A):

Q: What imaging modality is best for diagnosing and monitoring disease activity? A: FDG-PET/CT (shows active glucose uptake in the inflamed vessel wall) or MR Angiography.
Q: What is the classic angiographic/CT sign? A: The "macaroni sign" (diffuse, smooth, uniform wall thickening).
Q: Which arteries are most commonly involved? A: The subclavian arteries (causing arm claudication and asymmetric blood pressures).
Q: How does this differ demographically from Giant Cell Arteritis (GCA)? A: Takayasu affects young patients (usually < 40), often Asian females. GCA affects older patients (> 50).
Q: What cardiac valve is most commonly affected? A: The Aortic Valve (Aortic Regurgitation occurs due to dilation of the inflamed aortic root).

9. Why is the liver pulsatile in severe TR?

Response Template: Physiological Principle: The hepatic veins drain directly into the Inferior Vena Cava (IVC) and Right Atrium (RA) without any intervening valves. Pathophysiology: In severe Tricuspid Regurgitation (TR), the Right Ventricle contracts and ejects a massive volume of blood backward through the incompetent tricuspid valve into the RA. This creates a giant, systolic 'v' wave. Because there are no valves to stop it, this high-pressure kinetic wave transmits directly down the IVC into the hepatic venous system. Guideline Application: This causes systolic expansion of the liver capsule, felt clinically as a pulsatile liver. It is a hallmark of severe TR and right heart failure, indicating the need for aggressive diuresis and evaluation for tricuspid valve intervention (repair, replacement, or TEER).
Cross-Examination (5 Q&A):

Q: What does chronic hepatic congestion lead to? A: Cardiac cirrhosis (centrilobular necrosis and fibrosis).
Q: What happens to the JVP 'x' descent in severe TR? A: It is obliterated by the massive regurgitant 'v' wave, forming a fused 'cv' wave.
Q: What is Carvallo's sign? A: The pansystolic murmur of TR becomes louder with inspiration (distinguishing it from Mitral Regurgitation).
Q: What is the most common cause of TR? A: Functional (secondary) TR due to RV/RA dilation and annular stretching (not primary leaflet disease).
Q: If the liver is pulsatile in PRESYSTOLE, what is the cause? A: Tricuspid Stenosis or severe RV Hypertrophy (giant 'a' wave from atrial contraction).

10. Describe the "Graham Steell" murmur mechanism.

Response Template: Physiological Principle: The pulmonary valve normally withstands low diastolic pressures (~10-15 mmHg). Pathophysiology: In severe Pulmonary Hypertension (PHTN), the main pulmonary artery dilates massively. This physically stretches the pulmonary valve ring, pulling the leaflets apart and causing functional Pulmonary Regurgitation (PR). The high diastolic pressure gradient between the PA and the RV drives a high-velocity regurgitant jet. Guideline Application: This creates the Graham Steell murmur—a high-pitched, early diastolic, decrescendo murmur best heard at the left upper sternal border. It is a sign of advanced right-sided pressure overload. Treatment targets the underlying cause of the PHTN (e.g., Mitral Stenosis, PAH).
Cross-Examination (5 Q&A):

Q: Which left-sided valvular lesion is most classically associated with this murmur? A: Rheumatic Mitral Stenosis (Group 2 PHTN).
Q: How do you clinically distinguish the Graham Steell murmur from Aortic Regurgitation? A: AR has bounding peripheral pulses and a wide pulse pressure; Graham Steell does not.
Q: What happens to the intensity of the Graham Steell murmur with inspiration? A: It typically increases (like all right-sided murmurs).
Q: Does the Graham Steell murmur persist if the PHTN is cured? A: Usually no; once PA pressures normalize, the annulus shrinks and the valve becomes competent again.
Q: What does the ECG typically show in a patient with a Graham Steell murmur? A: Right Ventricular Hypertrophy (tall R in V1) and Right Axis Deviation.

11. Why is Pregnancy high-risk in severe MS?

Response Template: Physiological Principle: Normal pregnancy requires a 40-50% increase in blood volume and a 15-20% increase in resting heart rate to meet fetal metabolic demands. Pathophysiology: In Mitral Stenosis (MS), the Left Atrium requires a long diastolic filling time to push blood across the stenotic valve. The pregnancy-induced tachycardia shortens diastole severely. The combination of massive extra volume and less time to empty causes the LA pressure to rise exponentially. Guideline Application: This leads to flash pulmonary edema, most commonly in the late second trimester or during labor. ESC guidelines mandate intervention (PTMC is preferred) before pregnancy if the valve area is < 1.5 cm2. If symptoms develop during pregnancy despite beta-blockers, PTMC can be performed cautiously in the second trimester.
Cross-Examination (5 Q&A):

Q: Why is the immediate post-partum period (first 24-48 hours) the most dangerous time? A: Uterine contraction (auto-transfusion) and relief of caval compression rapidly shift 500-1000 mL of blood into the central circulation, overwhelming the stenotic valve.
Q: Which beta-blockers are preferred during pregnancy? A: Metoprolol or Labetalol. (Atenolol is avoided due to fetal growth restriction).
Q: If the patient develops Atrial Fibrillation, what anticoagulant is used? A: Low Molecular Weight Heparin (LMWH) with anti-Xa monitoring, as Warfarin is teratogenic in the first trimester.
Q: Can a pregnant patient undergo open-heart surgery for MS? A: Only as an absolute last resort (Class IIb) due to a 20-30% fetal mortality rate on cardiopulmonary bypass.
Q: How is labor ideally managed? A: Vaginal delivery with early epidural (to prevent tachycardia from pain) and assisted second stage (forceps/vacuum to avoid Valsalva).

12. Mechanism of "End-organ damage" in hypertensive emergency.

Response Template: Physiological Principle: Vascular beds possess autoregulation, constricting or dilating to maintain constant capillary blood flow across a wide range of blood pressures. Pathophysiology: In a hypertensive emergency (e.g., BP > 180/120), the pressure exceeds the upper limit of autoregulation. The overwhelming mechanical stress strips the endothelium and causes fibrinoid necrosis of the arterioles. This triggers a massive inflammatory cascade, local coagulation, and microangiopathic hemolytic anemia, leading to acute ischemia in the brain, heart, and kidneys. Guideline Application: Blood pressure must be lowered immediately with IV titratable agents (Labetalol, Nicardipine). However, to prevent watershed ischemia in organs newly adapted to high pressures, MAP should only be reduced by a maximum of 25% in the first hour, except in aortic dissection where rapid, aggressive reduction is mandatory.
Cross-Examination (5 Q&A):

Q: What defines a Hypertensive Emergency versus Hypertensive Urgency? A: The presence of acute, ongoing target-organ damage (e.g., encephalopathy, acute pulmonary edema, AKI), regardless of the absolute BP number.

Q: What fundoscopic finding is classic for hypertensive emergency (malignant hypertension)? A: Papilledema (Grade IV retinopathy).

Q: Why is oral Nifedipine (sublingual) absolutely contraindicated? A: It causes an unpredictable, precipitous drop in BP, leading to fatal strokes or myocardial infarctions.

Q: In acute ischemic stroke, what is the BP threshold to treat if giving tPA? A: Must be lowered to < 185/110 mmHg.

Q: What is the drug of choice for hypertensive emergency in pregnancy (Eclampsia)? A: IV Labetalol or IV Hydralazine, plus Magnesium Sulfate for seizure prophylaxis.

13. Pathophysiology of "Cardiac Amyloid" (restrictive).

Response Template: Physiological Principle: Normal myocardium relies on the elasticity of the extracellular matrix for diastolic filling. Pathophysiology: In Cardiac Amyloidosis, misfolded precursor proteins (Light chains in AL, or Transthyretin in ATTR) aggregate into insoluble beta-pleated sheets. These massive fibril deposits infiltrate the extracellular space, pushing myocytes apart and replacing elastic tissue with rigid amyloid. The myocardium becomes massively thickened and extremely stiff. Guideline Application: This creates severe Restrictive Cardiomyopathy (HFpEF). Because the walls are stiff, diastolic filling pressures skyrocket while stroke volume remains low. Treatment focuses on stopping fibril production (Chemotherapy for AL; Tafamidis for ATTR) and cautious diuresis. Standard HF drugs (Beta-blockers, ACEi) are poorly tolerated.
Cross-Examination (5 Q&A):

Q: What is the classic discrepancy between the ECG and the Echocardiogram? A: Low QRS voltages on ECG despite massive ventricular thickening on Echo.
Q: Why are Beta-blockers and CCBs poorly tolerated? A: The stroke volume is fixed due to the stiff ventricle; cardiac output is entirely dependent on heart rate. Slowing the HR causes cardiogenic shock.
Q: Which type of amyloid is diagnosed using a 99mTc-PYP bone scan? A: ATTR (Transthyretin) amyloidosis lights up on bone scans; AL does not.
Q: What is "Apical Sparing" on Echo strain imaging? A: Longitudinal strain is severely reduced in the basal and mid-ventricle but preserved at the apex (classic for amyloid).
Q: Can cardiac amyloid affect the atria? A: Yes, it infiltrates the atria extensively, causing massive dilation, AFib, and a high risk of thrombus even in sinus rhythm.

14. Why is iron deficiency common in chronic HF?

Response Template: Physiological Principle: Iron is critical not just for hemoglobin, but for mitochondrial function and ATP production in cardiomyocytes and skeletal muscle. Pathophysiology: Chronic heart failure is a state of systemic inflammation. Inflammatory cytokines (IL-6) stimulate the liver to produce Hepcidin. Hepcidin blocks ferroportin, trapping iron inside macrophages and preventing iron absorption from the gut. Furthermore, right-sided heart failure causes gut wall edema, physically impairing nutrient absorption. Guideline Application: This creates a functional iron deficiency, causing severe fatigue and worsening HF independent of anemia. Oral iron is ineffective due to poor absorption. ESC guidelines mandate IV iron replacement (Ferric Carboxymaltose or Derisomaltose) in symptomatic HFrEF patients with Ferritin < 100 ng/mL (or 100-299 ng/mL with TSAT < 20%) to improve symptoms and reduce hospitalizations.
Cross-Examination (5 Q&A):

Q: Does treating iron deficiency in HF improve mortality? A: Current trials (AFFIRM-AHF, IRONMAN) show significant reductions in hospitalizations and improved quality of life, though mortality benefit is not definitive.
Q: Can you have functional iron deficiency with normal hemoglobin? A: Yes, iron deficiency in HF causes cellular metabolic failure (fatigue) long before clinical anemia develops.
Q: Why is oral iron not recommended? A: The IRONOUT-HF trial showed oral iron is ineffective at replenishing stores in HF due to hepcidin-mediated gut block and GI intolerance.
Q: What is TSAT? A: Transferrin Saturation (Serum Iron / Total Iron Binding Capacity x 100).
Q: How often should iron studies be checked in HFrEF? A: At least once a year, or if symptoms worsen.

15. Mechanism of "Cardiac Resynchronization Therapy."

Response Template: Physiological Principle: Normal Purkinje conduction activates the LV septum and lateral wall simultaneously, maximizing ejection efficiency. Pathophysiology: In Left Bundle Branch Block (LBBB), electrical activation travels slowly through myocardial muscle cells rather than the fast conduction system. The septum contracts early, while the lateral wall contracts late. This severe mechanical dyssynchrony forces the lateral wall to contract against a high-pressure, already-emptying cavity, wasting energy and causing paradoxical septal motion and secondary Mitral Regurgitation. Guideline Application: CRT uses a pacemaker lead in a coronary sinus branch to pace the late-activating lateral wall simultaneously with the RV. This eliminates the dyssynchrony, instantly improving stroke volume, reducing MR, and driving long-term reverse remodeling.
Cross-Examination (5 Q&A):

Q: What QRS duration offers the most definitive benefit for CRT? A: QRS duration >= 150 ms (Class I indication).
Q: Is CRT effective for Right Bundle Branch Block (RBBB)? A: No, RBBB delays RV contraction, but LV synchrony is largely preserved. (Class IIb/III indication unless QRS is massively prolonged).
Q: What defines a "super-responder" to CRT? A: A patient whose LVEF normalizes (>50%) and LV volumes return to normal sizes after pacing.
Q: Where is the optimal placement for the LV lead? A: A lateral or posterolateral cardiac vein.
Q: What happens if the LV lead is placed too close to the phrenic nerve? A: Diaphragmatic stimulation (hiccups) during pacing.

16. Why do we avoid ACEi in "Bilateral Renal Artery Stenosis"?

Response Template: Physiological Principle: Glomerular Filtration Rate (GFR) depends on the hydrostatic pressure gradient across the glomerulus, regulated by afferent and efferent arteriolar tone. Pathophysiology: In bilateral renal artery stenosis, total renal perfusion is severely compromised. The kidneys survive entirely by hypersecreting renin, generating Angiotensin II. Ang II selectively constricts the efferent arteriole, acting as a "dam" to artificially maintain glomerular pressure and GFR despite low incoming flow. Guideline Application: Administering an ACE inhibitor or ARB removes Angiotensin II. The efferent arteriole immediately dilates, the "dam" breaks, and glomerular pressure plummets. This causes acute, severe oliguric renal failure. ACEi/ARBs are strictly contraindicated in bilateral stenosis (or unilateral stenosis in a solitary kidney).
Cross-Examination (5 Q&A):

Q: Can you use an ACEi in unilateral renal artery stenosis (with two functioning kidneys)? A: Yes, it is the treatment of choice for hypertension. The stenotic kidney will fail, but the normal kidney will easily handle the total GFR.
Q: What clinical finding suggests renal artery stenosis on physical exam? A: An abdominal bruit radiating to the flanks.
Q: What is the most common cause of RAS in older adults? A: Atherosclerosis.
Q: What is the most common cause of RAS in young females? A: Fibromuscular Dysplasia (FMD).
Q: What does the renal angiogram show in FMD? A: The classic "string of beads" appearance.

17. Pathophysiology of "Scleroderma Heart Disease."

Response Template: Physiological Principle: Scleroderma (Systemic Sclerosis) is driven by unchecked autoimmune fibroblast activation and microvascular injury. Pathophysiology: In the heart, repeated intense vasospasm of the coronary microcirculation (a "cardiac Raynaud's phenomenon") causes recurrent ischemia-reperfusion injury. Over time, this leads to patchy, focal "contraction band necrosis" and replacement fibrosis scattered throughout the myocardium, completely independent of epicardial coronary artery disease. Guideline Application: This massive interstitial fibrosis produces a severe restrictive cardiomyopathy (HFpEF) and lethal arrhythmias. Concurrently, pulmonary vascular fibrosis drives severe Group 1 PAH. Management relies on aggressive vasodilation (CCBs, PDE5i) and immunosuppression, though cardiac prognosis remains poor.
Cross-Examination (5 Q&A):

Q: Does scleroderma typically cause HFrEF or HFpEF? A: HFpEF (restrictive physiology due to stiff fibrotic walls).
Q: What is the most common cardiac manifestation in scleroderma overall? A: Asymptomatic pericardial effusion (present in up to 40% of patients).
Q: Is epicardial coronary stenting effective for their cardiac ischemia? A: No, the epicardial arteries are usually completely normal; the disease is microvascular.
Q: What triggers a "Scleroderma Renal Crisis"? A: High-dose corticosteroid use.
Q: How is Scleroderma Renal Crisis treated? A: Lifesaving administration of ACE inhibitors (even if creatinine is highly elevated).

18. What is the role of "Colchicine" in pericarditis?

Response Template: Physiological Principle: Acute pericarditis is driven by the innate immune system, specifically the assembly of the NLRP3 inflammasome in response to viral or sterile injury. Pathophysiology: Colchicine binds to tubulin in inflammatory cells, halting microtubule polymerization. This cripples neutrophil motility, prevents degranulation, and directly inhibits the assembly of the NLRP3 inflammasome, effectively shutting down the inflammatory cascade at its source. Guideline Application: Based on the ICAP and COPPS trials, Colchicine is a Class I recommendation as a first-line adjunct to NSAIDs for the first episode of acute pericarditis (to speed recovery) and is mandatory for recurrent pericarditis (to prevent future flares). It is typically dosed for 3 months (acute) or 6 months (recurrent).
Cross-Examination (5 Q&A):

Q: What is the most common side effect limiting Colchicine use? A: Gastrointestinal toxicity (severe diarrhea).
Q: Are corticosteroids first-line for acute pericarditis? A: No, they are a second-line option because they significantly increase the risk of recurrent pericarditis once tapered.
Q: What ECG finding is pathognomonic for acute pericarditis? A: Diffuse, concave ST-segment elevations with reciprocal PR-segment depressions (especially in lead II).
Q: How do you differentiate pericarditis ST elevation from STEMI ST elevation? A: STEMI is convex ("tombstone"), localized to a coronary territory, and has reciprocal ST depressions.
Q: Is Colchicine dosing adjusted for weight? A: Yes, typically 0.5 mg once daily for <70 kg, and 0.5 mg twice daily for >70 kg.

19. Explain "Electrical Alternans" in tamponade.

Response Template: Physiological Principle: The amplitude of a QRS complex on an ECG is directly proportional to the physical distance between the myocardium and the chest wall electrodes. Pathophysiology: In cardiac tamponade, a massive, tense pericardial effusion surrounds the heart. The heart literally detaches from its usual anatomic restraints and swings freely like a pendulum within the fluid-filled sac (a "swinging heart"). On beat one, the heart swings close to the chest wall (creating a tall QRS). On beat two, it swings backward, away from the chest wall (creating a short QRS). Guideline Application: This beat-to-beat variation in QRS amplitude (Electrical Alternans) is highly specific for a massive pericardial effusion/tamponade, demanding immediate echocardiography and preparation for pericardiocentesis.
Cross-Examination (5 Q&A):

Q: Is Electrical Alternans highly sensitive for tamponade? A: No, it is highly specific but lacks sensitivity (many tamponades do not show it).
Q: Does it only affect the QRS complex? A: Total electrical alternans involves the P wave, QRS, and T wave, but QRS is most commonly recognized.
Q: Can Electrical Alternans occur in non-tamponade conditions? A: Yes, it can be seen in severe LV dysfunction (pulsus alternans equivalent) or SVT/WPW (due to alternating refractory periods).
Q: What is the most definitive Echo sign of Tamponade? A: Early diastolic collapse of the Right Ventricle.
Q: If a patient has tamponade physiology but no fluid is seen, what is the diagnosis? A: Effusive-constrictive pericarditis or pure constrictive pericarditis.

20. Why do we use "Beta-blockers" in HCM?

Response Template: Physiological Principle: In Hypertrophic Cardiomyopathy (HCM), the Venturi effect causes Systolic Anterior Motion (SAM) of the mitral valve, generating dynamic LVOT obstruction. The gradient is driven by high ejection velocities and small LV cavity size. Pathophysiology: Beta-blockers are negative inotropes and negative chronotropes. By reducing inotropy (contractility), they slow the ejection velocity of blood, reducing the Venturi forces that pull the mitral valve into the septum. By reducing chronotropy (heart rate), they prolong diastole, allowing more time for the stiff, non-compliant LV to fill. The increased LV volume physically separates the septum from the mitral valve, drastically reducing the gradient. Guideline Application: Non-vasodilating Beta-blockers (e.g., Metoprolol, Bisoprolol) are the Class I first-line pharmacotherapy for symptomatic obstructive HCM. Vasodilators (Nitrates, ACEi) are strictly contraindicated as they shrink the LV cavity and worsen SAM.
Cross-Examination (5 Q&A):

Q: If beta-blockers fail, what is the next pharmacological option? A: Non-dihydropyridine CCBs (Verapamil/Diltiazem) or the cardiac myosin inhibitor Mavacamten.
Q: Why is Mavacamten groundbreaking? A: It directly targets the underlying molecular defect (excess actin-myosin cross-bridging), relaxing the muscle and abolishing the gradient.
Q: What is a major risk of Verapamil in severe HCM? A: It has mild vasodilatory properties; if the gradient is extremely high (>100 mmHg), it can cause catastrophic hypotension and pulmonary edema.
Q: If medical therapy fails, what are the invasive options? A: Surgical Septal Myectomy (gold standard) or Alcohol Septal Ablation.
Q: Does relief of the LVOT gradient prevent sudden cardiac death? A: No, the risk of lethal arrhythmias (VT/VF) remains; patients must be risk-stratified for an ICD regardless of their obstruction status.

Dr Sidhartha Mullapudi

Search This Blog